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INTRODUCTION 
 
MELANOMA  
Malignant melanoma is a very aggressive, therapy-resistant malignancy due to 
transformation and uncontrolled growth of melanocytes, the pigment-producing cells that 
reside in the basal epidermal layer of the skin (Figure 1) (1). The first accredited report of 
melanoma is found in the writings of Hippocrates (born c. 460 BC), where he described “fatal 
black tumors with metastases.” In 1960s paleopathologists discovered diffuse bony 
metastases and round melanocytic masses in the skin of Peruvian mummies, radiocarbon 
dated to be approximately 2400 years old (2). However, it was not until 1806, when René 
Laennec described “la mélanose” to the Faculté de Médecine in Paris, that the disease was 
characterized in detail and named (3). General practitioner William Norris suggested that 
melanoma may be hereditary in an 1820 manuscript describing a family with numerous 
moles and several family members with metastatic lesions (4). Molecular insights over the 
past 20 years have confirmed Norris’s theory of a significant genetic contribution to the 
etiology of melanoma. The first formal acknowledgment of advanced melanoma as 
untreatable came from Samuel Cooper in 1840. He stated that the only chance for benefit 
depends upon the early removal of the disease. More than one and a half centuries later this 
situation remains largely unchanged. 
Melanoma is the fifth most common cancer in men and the seventh in women and 
comprises 4% of all cancers in the United States (5). Since the mid 1960s, melanoma 
incidence has risen by 3–8% per year in most people of European background, with the 
greatest increases in elderly men (6). Although melanoma accounts for only 3% of all 
dermatologic cancers, it is responsible for 65% of skin malignancy-related deaths, and the 5-
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year survival of metastatic cutaneous melanoma patients is only 7-19% (7;8). Around 
160,000 new cases of melanoma are diagnosed worldwide each year, (9;10) and, according 
to the 2006 WHO report, about 48,000 melanoma-related deaths occur each year. Incidence 
rates in Southern and Eastern European countries were fairly low, ranging between 2 and 8 
per 100,000 in most countries (11).  
More than 95% of tumors are found in the skin, however melanoma is not exclusively 
a skin cancer: sites of primary extracutaneous melanoma include ocular, mucosal, 
gastrointestinal, genitourinary, leptomeninges (12).  
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Figure 1: Phases of histologic progression of melanocyte transformation (taken from (13)).  
Hematossilin-Eosin (H&E) stained histologic sections and corresponding pictorial representation. (A) 
Normal skin. There is even distribution of normal dendritic melanocytes in the basal epithelial layer. 
(B) RGP in situ melanoma. Melanoma cells have migrated into the upper epidermis (pagetoid spread) 
and are scattered among epithelial cells in a “buckshot” manner. Cells have not penetrated the 
epidermal basement membrane. Melanoma cells show cytologic atypia, with large abundant 
cytoplasm and increased overall size compared with normal melanocytes. Nuclei are enlarged and 
hyperchromatic. Commonly, there is more junctional melanocytic hyperplasia (nests of tumor cells at 
the basement membrane zone) in RGP melanoma than portrayed in the histologic example. (C) VGP 
malignant melanoma. Melanoma cells show pagetoid spread and have penetrated the dermal-
epidermal junction. Melanoma cells show cytologic atypia. Cells in the dermis cluster or individually 
invade. Magnification, ×20. Scale bar: 20 μm. 
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Epidemiology  
Risk factors that contributes to the genesis of melanoma are divided in two groups: 
environmental and intrinsic factors (14;15). The most relevant environmental factor is 
intermittent sun exposure, while intrinsic factors are represented by individual's family 
history and inherited genotype.  
Epidemiologic studies suggest that exposure to ultraviolet radiation (UVA and UVB) 
(16) is one of the major contributors to the development of melanoma. UV radiation 
promotes damages to the skin by having direct mutagenic effects on DNA, by reducing 
cutaneous immune defenses, and by inducing the formation of reactive oxygen species of 
melanin that cause DNA damage and suppress apoptosis (17). Solar radiation also increases 
the local production of growth factors, such as stem cell factor, fibroblast growth factor and 
transforming growth factor α. Resulting signals are traduced via the Ras/RAF pathway, 
ultimately triggering the transcription of genes involved in cellular proliferation and 
migration (Figure 2) (6). Possible significant elements in determining the risk of developing 
melanoma include the intensity and duration of sun exposure, the age at which sun 
exposure occurs, and the degree of skin pigmentation. Individuals with blistering or peeling 
sunburns (especially in the first two decades of life) have a significantly greater risk for 
developing melanoma in their adulthood. Fair and red-headed people, persons with multiple 
atypical nevi or dysplastic nevi and persons born with giant congenital melanocytic nevi have 
an increased risk (18). Melanoma is more common on the back in men and on legs in women 
(areas of intermittent sun exposure). The risk appears to be strongly influenced by socio-
economic conditions rather than indoor versus outdoor occupations; it is more common in 
professional and administrative workers than unskilled workers (19;20).  
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Intrinsic factors include mutations in or total loss of selected Tumor Suppressor 
Genes (TSGs). Familial melanoma patients tend to have an earlier age at first melanoma 
diagnosis, thinner tumors, and a higher frequency of multiple primary melanomas (MPMs) 
than patients who have sporadic melanoma (21). A family history of melanoma greatly 
increases a person's risk because of mutations in three high-penetrance and one low-
penetrance melanoma predisposing genes. The best-characterized high-penetrance gene 
locus is on chromosome 9p21, CDKN2A (cyclin-dependent kinase inhibitor 2A). By using 
different first exons, 1a and 1b, respectively, CDKN2A encodes two unrelated proteins, 
p16INK4A (commonly referred to as p16) and p14ARF (alternative reading frame), which are 
both tumor suppressors involved in cell cycle regulation. This genetic locus is frequently 
alterated in melanoma and germline mutations, in one or both of these gene products, are 
inherited in certain melanoma-prone families (22). When defective, p16 is unable to 
inactivate CDK4 and CDK6, which phosphorylate Rb, releasing the transcription factor E2F 
and leading to cell cycle progression. Mutations in p14ARF allows the release of hdm2, 
resulting in degradation of p53 gene, central to protection against DNA damage by triggering 
cell cycle arrest or apoptotic cell death (Figure 2) (6). Relative risk of carrying a CDKN2A 
mutation for melanoma patients was demonstrated to significantly increase with the 
presence of familial occurrence of melanoma, MPMs, and early age of onset. In Italy, the 
prevalence of CDKN2A germline mutations may vary widely among patients with different 
geographical origins: its frequency is higher in patients from Northern Italy in comparison to 
those from Southern Italy (23). The third high penetrance melanoma predisposition gene, 
CDK4 (cyclin dependent kinase 4), is located on 12q13. Mutations in these gene products are 
inherited in an autosomal dominant fashion and confer ‘extremely high risk’ (24). 
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Conversely, MC1R, the melanocortin receptor gene, located on 16q24.3, is a low-penetrance 
gene. This gene encodes the G-protein coupled receptor for α-melanocyte stimulating 
hormone (α-MSH) (25). Binding of α-MSH to the receptor increases the expression of 
enzymes involved in the production of melanin in melanocytes. Light-skinned people often 
carry germ-line polimorphisms in the MCR1 gene, that reduces the activity of the receptor. 
(17). MC1R variants seem to increase melanoma risk in families with CDKN2A mutations. 
Recently, a synergistic relationship between germline MC1R variants and somatic v-raf-
murine sarcoma viral oncogene homolog B1 (BRAF) mutations has been suggested, whereby 
MC1R variant genotypes seem to confer a significantly increased risk of developing BRAF-
mutant melanoma in skin not damaged by sunlight. It has been hypothesized that 
intermittent sun exposure may indirectly induce BRAF mutations through the impairment of 
MC1R and an increased production of free radicals (23). Worldwide it has been estimated 
that approximately 20%-40% of kindreds that have familial melanoma are related to 
germline CDKN2A mutations (21), and only 1%-2% of known melanoma family carry 
mutations in CDK4 or ARF-only genes (24). The incidence of melanoma has increased in the 
recent years, but it is not clear to what extent changes in behavior, in the environment, or in 
early detection are involved (26;27). 
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Figure 2: Selected prominent molecular pathways in the genesis and regulation of melanoma (taken from 
(6)). 
Targets undergoing experimental inhibition in melanoma therapy (green diamonds): (1) antisense 
oligonucleotide to Bcl-2 (oblimersen); (2) CDK inhibitors (flavopiridol); (3) receptor tyrosine kinase inhibitors; 
(4) farnesyl transferase inhibitors; (5) RAF inhibitors (BAY 43-9006); (6) mTOR inhibitors. Barred lines indicate 
inhibition. SCF=stem cell factor. FGF=fibroblast growth factor. Ras=rous avian sarcoma homologue. BRAF=v-raf 
murine sarcoma viral oncogene homologue B1. MEK=mitogen-activated protein kinase kinase (MAP2K). 
ERK=extracellular signal-regulated kinase. MAPK=mitogen-activated protein kinase. Mitf=microphthalmia 
transcription factor. PI3K=phosphatidylinositol-3 kinase. Akt=murine v-akt oncogene homologue. 
mTOR=mammalian target of rapamycin. CDKN2A=cyclin dependent kinase inhibitor-2A. CDK=cyclin dependent 
kinase. Rb=retinoblastoma protein. p16=16.000 MW protein. ARF (p14ARF)=14.000 MW alternate reading 
frame protein. cAMP=cyclic AMP. Bcl=B-cell lymphoma derived protein. hdm=human double minute 
chromosome-associated protein. E2F: E2F cell cycle regulated transcription factor. MSH=melanocyte 
stimulating hormone (melanocortin). MC1R=melanocortin-1 receptor. 
 
Clinical classification  
Historically, malignant melanoma was classified first by Wallace Clark  and coworkers 
(28), and later by Richard Reed, who added another type of melanoma (29). Nowadays the 
classification comprises: Superficial Spreading Melanoma (SSM), that can occur at any site 
and at any age (relative incidence: 50-70%); Nodular Melanoma (NM), that has no radial 
growth phase and could be nodular, polypoid, or peduncolated (relative incidence: 15%-
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35%); Lentigo Maligna Melanoma (LMM), that occurs on the sun-exposed skin, face and 
upper estremities of elderly patients (relative incidence: 5-15%), Acral Lentiginous 
Melanoma (ALM), that is common on palmar, plantar and ungula skin of Black and Japanese 
people (relative incidence: 5-10%), Desmoplastic melanoma (DM) (uncommon), 
miscellaneous group (rare) (13). 
 
Prognostic factors 
Adverse prognostic factors in melanoma comprises: pathological, clinical and other 
factors, including genetic alteration.  
The first group includes increase of tumor thickness in millimeters (Breslow's depth), 
presence of ulceration, depth related to skin structures (Clark level), absent or non-brisk 
tumor infiltrating lymphocytes, presence of microscopic satellites (30), mitotic rate, 
lymphovascular invasion, angiotropism, neurotropism, histologic signs of tumor regression, 
tumor volume, cell type, local recurrence, presence of vertical growth phase and an elevated 
concentration of LDH in serum (for stage IV melanoma patients) (31). 
Clinical adverse factors include increasing age, male sex, tumor location on the trunk, 
head or neck, and regional or distant metastasis (13). When there is distant metastasis, 
melanoma is generally considered incurable. The five year survival rate is less than 10% (7). 
Most patients with metastatic disease confined to the skin, subcutis, lymph nodes and lungs 
have a better prognosis (median survival: 12 months), whereas metastases to brain, bone 
and liver are associated with a worse prognosis (median survival: 4-6 months) (6). In some 
cases, however, patients may live many months or even years with metastatic melanoma. 
Treatment is palliative, focusing on life-extension and quality of life. 
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Development and progression  
Melanoma has been hypothesized to result from the transformation of a cutaneous 
melanocyte through nevus and dysplastic nevus stages to in situ and eventually invasive 
melanoma. The traditional model suggests that melanomas initially develop in the epidermis 
and then invade the dermis. A recent research reveals that melanocytes can be transformed 
with oncogenes and acquire malignant/invasive characteristics (32). Melanoma arises due to 
accumulation of mutation in genes critical for cell proliferation, differentiation, and cell 
death. As additional mutations accumulate, melanoma cells acquire the ability to initiate and 
sustain angiogenesis, invade across tissue planes, and metastasize. Moreover, melanomas 
are largely growth factor-independent, presumably due to mutations, such as NRAS and 
BRAF activation or phosphatase and tensin homolog (PTEN) inactivation, that promote 
proliferation and survival (33) or to autocrine signaling loops deriving from activation of 
pathways leading to the production of their own growth factors. This independence from 
homeostatic pathways allows the tumors to thrive in non-epidermal environments (34). The 
initiation and progression of melanoma are accompanied by a series of histologic changes, 
which are described in the Clark model. The five distinct stages in this model include (Figure 
1 and 3): 
1) nevus, a benign lesion characterized by an increased number of nested melanocytes; 
2) dysplastic nevus, characterized by random and discontiguous cytologic atypia; 
3) radial-growth phase (RGP) melanoma, where the cells acquire the ability to proliferate 
intraepidermally; 
4) vertical-growth phase (VGP) melanoma, where the cells acquire the ability to penetrate 
through the basement membrane into the underlying dermis and subcutaneous tissue; 
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5) metastatic melanoma, characterized by the spread of cells to other areas of the skin and 
other organs. 
The most critical event along this progression line is probably the transition from RGP to 
VGP, which involves the escape from keratinocyte-mediated growth control, consistent with 
tumor thickness being one of the strongest predictors of metastatic disease and adverse 
clinical outcome (35). 
 
 
Figure 3: Biologic Events and Molecular Changes in the Progression of Melanoma (adapted from (17)). 
At the stage of the benign nevus, BRAF mutation and activation of the mitogen-activated protein kinase 
(MAPK) pathway occur. The cytologic atypia in dysplastic nevi reflect lesions within the cyclin-dependent kinase 
inhibitor 2A (CDKN2A) and phosphatase and tensin homologue (PTEN) pathways. The vertical-growth phase 
and metastatic melanoma are notable for striking changes in the control of cell adhesion. Other changes 
include the loss of E-cadherin and increased expression of Ncadherin.  
 
The pathogenetic mechanisms underlying melanoma development are still largely 
unknown, nevertheless, several metabolic pathways (e.g. mitogen-activated protein kinase 
(MAPK), PI3K–AKT, β-catenin, senescence) have been shown to be targeted by classical 
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genetic alterations such as mutation, deletion and amplification, and to play an important 
role in melanoma biology. The activation of MAPK pathway through mutations of BRAF 
appears to be the most common. Notably, BRAF mutations have been found in up to 82% of 
benign nevi, thus suggesting that activation of the MAPK pathway is a necessary, but not 
sufficient, event for melanoma development (36;37).  Although the activation of the MAPK 
signaling has been recognized as a critical event, Khavari and colleagues have demonstrated 
that activation of BRAF–MAPK requires concomitant PI3K–AKT pathway alteration to affect 
melanoma development (1;32). Consistent with this data, over 60% of human melanomas 
exhibit activated AKT (38), and mutational inactivation and/or deletion of the PI3K negative 
regulator PTEN occurs in 30–40% of melanoma cell lines (39;40). 
 
BRAF mutations 
Since its discovery through a genome-wide cancer resequencing effort (41), 
mutations in BRAF have been detected in a variety of tumor types, with the highest 
incidence in melanoma (ranging from 27% to 70%) (15;42;43). BRAF is a component of the 
MAP kinase pathway, a signal transduction pathway that transmits mitogenic signals from 
activated cell surface growth factor receptors, under normal physiologic conditions, through 
the binding of BRAF with its substrate MAP kinase kinase (MEK) (44). Activating BRAF 
mutations are the most frequent (60%–80%) somatic genetic event in human melanoma 
(41;45). 80% of these mutations are found at exon 15, at a single amino acid residue, usually 
a substitution for valine by glutamic acid, V599E (now referred to as V600E). This mutation 
costitutively activates BRAF, provoking increased signaling through the MAP kinase pathway 
and causing activation of the Brn-3 transcription factor, which leads to unregulated cell 
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growth (46-49). Surprisingly, BRAF oncogenic mutation occurs at a similar high frequency 
(62–72%) in benign melanocytic nevi as well as in VGP, metastatic melanoma, and 
melanoma cell lines (45;50). In striking contrast, Dong et colleagues found BRAF lesions in 
only 10% of the earliest stage or RGP melanomas and concluded that BRAF mutations could 
be involved in the initiation of the great majority of melanomas but instead might be 
associated with disease progression (51).  
 
Metastatic melanoma 
Metastatic melanoma is an incurable disease with high mortality rate. Patients with 
metastatic disease have an average survival of <1 year. This high mortality rate is largely the 
result of the resistance to chemotherapy and radiotherapy (52). Various effectors, which up- 
or downregulate different molecular pathways, appear to be involved in progression of 
normal melanocyte to metastatic malignant cells (53). Numerous studies using tissue 
specimens, cell lines, and xenografts to discover the mechanism(s) behind this 
transformation, invasiveness, and metastasis are in progress. Alterations of cell cycle 
proteins (e.g., cyclin D1, pRb, and p16) have a role in transformation and progression in 
melanocytic tumors. It has been shown that progressive loss of p16 can result in 
transformation of benign nevi to melanoma and to metastatic melanoma. Progressive 
increase in expression of cyclin D1 and pRb is associated with progression to melanoma cells; 
however, cyclin D1 and pRb show relative decrease in thick melanoma and metastatic 
melanoma (54). Protein Kinase C (PKC) mediates signals for cell growth and is a target of 
tumor-promoting phorbol esters in malignant transformation (55). Higher expression of 
protease-activated receptor-1 (PAR-1) is seen in melanoma cell lines and tissue specimens. 
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Upregulation of PAR-1 mediates high levels of gap junctional intracellular communication 
molecule connexin (Cx-43) expression, a molecule involved in tumor cell diapedesis and 
attachment to endothelial cells (56). Type I collagenase and PAR-1 activating functions of 
matrix metalloproteinase-1 (MMP-1) are required for melanoma progression. Highly 
expressed MMP-1 is suggested to be involved in progression of noninvasive melanoma to 
invasive vertical growth phase by degrading type I collagen of skin (57). Downregulation of E-
cadherin and upregulation of N-cadherin may be seen in melanoma cells (Figure 3). Such 
shift of cadherin profile may have a role in uncontrolled proliferation, invasion, and 
migration (58). A recent study, based on the fact that angiogenesis is one of the factors 
required for progression and melanoma metastasis, demonstrated that vascular endothelial 
growth factor (VEGF) and its receptors (VEGF-R1, VEGF-R2, and VEGF-R3) are higher in 
melanomas and advanced melanomas than in benign nevi. VEGF-R2 shows higher expression 
in metastatic melanomas than in primary melanoma (59). Using immunoistochemistry on 
human tissue, it has been shown that there is significantly higher cortactin (a multidomain 
actin-binding protein important for the function of cytoskeleton) expression in melanomas 
than in nevi and higher expression in metastatic melanoma than in invasive primary 
melanomas (60). Moreover, major histocompatibility complex (MHC) molecule 
overexpression in earlier stages of melanoma and downregulation in metastatic malignant 
melanoma have been observed (61). Melanoma chondroitin sulfate proteoglycan (MCSP) 
facilitates the growth, motility, and invasiveness of tumor cells. MCSP expression is 
associated with increased expression of c-Met, resulting in growth and motility of melanoma 
cell lines (62).  
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MELANOMA THERAPEUTICS 
Treatment of advanced malignant melanoma is generally performed by a 
multidisciplinary approach. 
 
Surgery and radiotherapy 
Surgery is the first choice therapy for localized melanoma. Surgical treatment of 
melanoma employs complete surgical excision with adequate margins and assessment for 
the presence of detectable metastatic disease. Local recurrences and in-transit metastases 
are treated by surgical excision. Surgery can also be valuable for patients with evident 
metastatic disease in regional lymph nodes, or with surgically resectable disease in visceral 
sites. (6). Melanoma has long been considered relatively resistant to radiotherapy. However, 
surgical resection and radiation therapy also offer palliation in specific circumstances and 
radiotherapy remains the treatment of choice for treatment of multiple cerebral metastases, 
and of non-resectable bone metastases, with some success in controlling symptoms (63). 
 
Chemotherapy  
Among traditional chemotherapeutic agents, only dacarbazine (DTIC) is Food and 
Drug Administration (FDA) approved for the treatment of advanced melanoma (64). 
Combination chemotherapy regimens (such as cisplatin, vinblastine, and dacarbazine) are 
often employed, though no clinical trials have demonstrated a survival advantage for 
combination therapy over optimal single-agent therapy (64). Temozolomide is an oral 
alkylating agent approved for the treatment of malignant gliomas with activity comparable 
to that of dacarbazine in melanoma. While there is not yet supportive clinical trial data, 
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temozolomide has been substituted in many combination regimens and is under 
investigation in combination with radiation therapy for patients with melanoma metastatic 
to the brain (65). Nevertheless, these therapies are associated with response rates of only 10 
to 20% and a small percentage of complete responses; neither is thought to improve overall 
survival (66). In randomized trials, the median survival among patients treated with 
dacarbazine was less than 8 months (67).  
 
Targeted therapy 
Targeted therapy consists of a novel group of antibodies and small-molecule kinase 
inhibitors that specifically target proteins that are involved in growth signalling pathways in 
cancer cells. The identification of somatic mutations in BRAF in the majority of melanoma 
leads to the development of various targeted-therapies for this disease. Studies with BRAF 
inhibitors are currently ongoing but, despite good responses, patients with BRAF mutant 
tumors eventually develop resistance and disease progression. The first RAF kinase inhibitor 
entering early clinical trials was the oral diphenyl urea, sorafenib (Bay 43-9006) (Figure 2). It 
has minimum activity on its own, but in combination with the cytotoxic drugs carboplatin 
and paclitaxel it gave partial response in phase II trials (68). Further research led to the 
development of second generation more selective RAF inhibitors, which are currently in 
clinical trials. XL281 (famotidine) is an orally administered inhibitor of the wt BRAF (IC50 4.5 
nM), CRAF (IC50 2.5 nM) and mutant BRAFV600E (IC50 6nM) kinases and demonstrated potent 
inhibitory effect in human melanoma xenograft models (69). At the moment, the best two 
BRAF inhibitors tested in clinical studies are: PLX4032 and GSK2118436 (Figure 4), which are 
highly selective and provoke effects on proliferation and apoptosis only in cells harboring 
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BRAF mutations (44). In a phase II clinical trial for GSK2118436 has been reported an overall 
response rate of 77% and responses were seen in many sites, including brain (23). In a phase 
I/II study with PLX4032, in patients with tumors that carry the BRAFV600E mutation, a 
complete or partial tumor regression was observed in the majority of patients (70). 
Noteworthy, results from a very recent phase III clinical trial, comparing PLX4032 
(Vemurafenib) with dacarbazine, in 675 metastatic melanoma patients, showed that  
Vemurafenib improved the rates of response and of both progression-free and overall 
survival, as compared to dacarbazine alone, in patients with metastatic melanoma carrying 
BRAFV600E mutation (71). Based on these evidences, the prospect of using a number of 
targeted inhibitors in combination with chemotherapy provides some optimism. 
 
 
Figure 4: Inhibitors of the mitogenactivated protein (MAP) kinase pathway that currently are in clinical 
development (adapted from (44)). 
Nonselective Raf inhibitors have potency for v-raf-1 murine leukemia viral oncogene homolog 1 (RAF1) that is 
greater than or equal to their potency for v-raf murine sarcoma viral oncogene homolog B1 (BRAF). MEK 
indicates MAP kinase kinase; NRAS, neuroblastoma RAS viral oncogene homolog; CRAF, proto-oncogene c-RAF; 
Erk, extracellular signal-regulated kinase. 
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Immunotherapy 
New and innovative approaches and more effective therapies for advanced 
melanoma are needed. One approach that holds promise is immunotherapy. 
  Cancer immunotherapy targets the induction or augmentation of anticancer 
immune-response. The main premise is stimulating the patient's immune system to attack 
the malignant tumor cells that are responsible for the disease. This can be done either 
through the immunization of the patient by therapeutic vaccines, in which case the patient's 
own immune system is trained to recognize tumor cells as targets to be destroyed, or 
through the administration of therapeutic antibodies as drugs, in which case the patient's 
immune system is recruited to destroy tumor cells by the therapeutic antibodies. The 
phenotypic characterization of neoplastic cells and the definition of their functional 
interactions with host's immune system have provided a strong rationale for designing and 
applying in the clinic new strategies of cancer immunotherapy. A well known therapy in 
melanoma is based on the use of biologic agents that stimulate the immune system.  
A large, randomized multicenter study in high risk melanoma patients performed by 
the Eastern Cooperative Oncology Group (ECOG) showed significant improvements in 
relapse-free and overall survival with postoperative adjuvant IFN-α-2b therapy, compared 
with standard observation (ECOG 1684) (72). The outcome of this study led to FDA approval 
of IFN-α-2b for treatment of melanoma. This study was performed on patients with deep 
primary tumors without lymph node involvement and node-positive melanomas. In other 
studies, little antitumor activity has been demonstrated in IFN-α-2b–treated metastatic 
stage IV melanoma. Furthermore, while a large follow-up study (Intergroup E1690) (72) 
confirmed relapse-free survival with high-dose IFN-α-2b, it did not show an increase in 
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overall survival. Toxicities of high-dose IFN include constitutional (flulike) symptoms and 
neuropsychiatric (depression, suicidal intention), hematologic, and hepatic effects (72). 
Other studies of low-dose IFN versus either observation or high-dose IFN have not shown a 
statistically significant increase in overall survival (72). Interleukin-2 (IL-2) has been used for 
the treatment of melanoma with modest success for several decades. In recent trials, IL-2 
has been combined with other cytokines, such as granulocyte, macrophage, colony 
stimulating factor (GM-CSF). However, clinical response rates were not increased by adding 
GM-CSF to IL-2. There are many acute toxicities associated with Interleukin therapy and 
extremely close monitoring is essential for safe administration (73). 
In addition, a positive Phase III vaccination study was presented in metastatic 
melanoma, in which a melanocyte protein PMEL (also known as gp100) vaccine that was 
combined with high-dose IL‑2 was compared with high-dose IL‑2 alone; a statistically 
significant benefit in progression-free survival and a borderline significant benefit in overall 
survival was observed for the combination therapy (74). A recent approach to manipulate 
immune responses against neoplastic cells involves targeting by monoclonal antibodies 
(mAb) of cytotoxic T-lymphocyte antigen-4 (CTLA4), a key immune checkpoint molecule from 
the CD28:B7 family. Ipilimumab and Tremelimumab represent the prototypes of this 
growing class immunostimulating mAb. Both mAb were extensively tested in metastatic 
melanoma with highly promising results. In this regards, durable responses and disease 
stabilization have been demonstrated for ipilimumab in phase II clinical trials in advanced 
melanoma, with 3-year survival rates ranging from 23% to 34% (75-77). In the phase III, 
randomized, controlled trial MDX010-20, ipilimumab demonstrated a statistically significant 
improvement in overall survival in patients with previously treated, advanced melanoma 
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(78). Ipilimumab clinical activity appears to be independent of a number of negative 
prognostic factors (79), and response to treatment may follow a period of apparent disease 
progression (78;80). Noteworthy, the therapeutic activity of Ipilimumab was most recently 
studied also in a phase III study, in combination with dacarbazine, in patients with previously 
untreated metastatic melanoma (81). A significant improvement in overall survival was 
observed in the group receiving Ipilimumab plus dacarbazine, than in group receiving 
dacarbazine plus placebo (81). 
Other mechanisms of stimulating the immune system are currently under 
investigation in clinical trials and include active specific immunotherapeutic approaches, also 
defined as therapeutic vaccination. In particular, the identification of tumor-associated 
antigens (TAA) recognized by antibodies and/or cytotoxic T lymphocytes (CTL) (82), together 
with progresses in the knowledge on the molecular mechanisms regulating tumor-host 
interactions (16), prompted the development of different pre-clinical and clinical studies of 
specific immunotherapy. Among others, the cancer vaccines mostly utilized in the clinical 
setting are based on whole cancer cells, anti-idiotypic antibodies, DNA, recombinant 
proteins, peptides, autologous heat shock proteins, and peptide-/tumor-pulsed dendritic 
cells (82-84). 
 TAA-based immunotherapy is emerging as a promising and additional therapeutic 
option that is rapidly integrating in the overall treatment of cancer patients. 
According to their pattern of expression in neoplastic and normal tissues, TAA thus far 
identified can be classified in 9 groups including: 
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 a) Cancer Testis antigens (CTA), expressed in tumors of various histological origin but not in 
normal tissues other than testis and placenta (MAGE, SSX, NY-ESO families: GAGE,PAGE, 
XAGE superfamilies);  
b) Differentiation antigens, expressed in normal and neoplastic cells of the same lineage 
(e.g., Melan-A/MART-1, tyrosinase, gp-100);  
c) Over-expressed antigens, expressed at higher levels in malignant compared to benign 
tissues (e.g., HER2/neu, EpCAM);  
d) Tumor-specific unique antigens, arising from point mutations of normal genes, like β-
catenin and CDK-4, whose molecular changes often accompany neoplastic transformation or 
progression;  
e) Fusion proteins, deriving from translocation of chromosomes, resulting in the fusion of 
distant genes, and that characterize each type of disease (e.g., bcr-abl and pml-RARβ in 
chronic myelogenous leukemia and acute promyelocytic leukemia, respectively);  
f) Oncofetal antigens, expressed in fetal, neoplastic and specific benign adult tissues in 
quantitatively varying levels, often used as diagnostic or prognostic markers for malignancies 
(e.g., α-1-fetoprotein and carcinoembryonic antigen)  
g) Glycolipids and glycoproteins (i.e., high molecular weight-melanoma associated antigen 
(HMW-TAA), gangliosides and mucins), expressed at high levels and/or with an aberrant 
glycosylation status in malignancies of different histotype;  
h) Splice variants of known genes, identified by SEREX and found to be immunogenic in 
cancer patients (e.g., NY-CO-37/38);  
i) Cancer-related autoantigens, also identified by SEREX, are expressed ubiquitously and at a 
similar level in healthy and malignant tissues (e.g., CEBPγ). The encoding genes are not 
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altered in tumor samples; however, they elicit antibody responses in cancer patients but not 
in healthy individuals (85). 
 
CTA 
CTA are a large family of tumor-associated antigens expressed in human tumors of 
different histological origin, but not in normal tissues except for testis and placenta. This 
tumor-restricted pattern of expression, together with their restricted presentation by the 
HLA machinery on tumor cell surface (16;86;87), their shared expression by neoplasia of 
different histotype (88), and their ability to generate a spontaneous humoral and cellular 
immune response (82;89), identified CTA as ideal targets for tumor-specific 
immunotherapeutic approaches. Further support to the clinical important role of CTA, in 
cancer immunotherapy, derives from the correlation between the presence of anti-CTA 
humoral immune response and a more favorable clinical course of cm patients treated with 
ipilimumab (90). Among different CTA, recombinant proteins or HLA class I and HLA class II-
restricted antigenic peptides of MAGE, NY-ESO and SSX gene families and GAGE/PAGE/XAGE 
super-families have been utilized for cancer vaccination in clinical trials, resumed in Table 1 
(91). The clinical results emerged from the initial clinical trials indicated that CTA-based 
vaccination is a safe therapeutic procedure and that complete responses, as well as 
prolonged disease free survival, were observed in different solid tumors (82;84;92-94). Even 
if clinical results are encouraging, several issues are still to be optimized to improve the 
efficacy of CTA-based immunotherapy. In fact, clinically effective CTA-based vaccination of 
cancer patients faces two major obstacles: 1) the expression of a given therapeutic CTA in a 
limited percentage of cancer patients, (95) and 2) the highly heterogeneous intratumoral 
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distribution of CTA within distinct neoplastic lesions (95). The magnitude of the latter aspect 
appears evident when considering immunohistochemical data reporting that the majority of 
CTA-positive neoplastic lesions show CTA staining in less than 50% of neoplastic cells (96). 
This feature of CTA poses a major obstacle for the clinical success of CTA-based vaccination 
since CTA-negative cancer cells within CTA-positive neoplastic lesions should be able to 
circumvent vaccination-induced CTA-specific immune recognition, allowing the outgrowth of 
a CTA-negative malignant lesion. 
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Table 1: Ongoing clinical trials with CTA in melanoma (adapted from (91)). 
CTA Sponsor Phase Combination Identifier 
MAGE-A3 
(
a
GSK2132231A) 
Glaxo Smith 
Kline 
I Dacarbazine NCT00849875 
MAGE-A10, NY-
ESO-1, Melan-A 
Ludwig 
Institute for 
Cancer 
Research 
I a) Montanide + Melan-A analogue peptide 
b) Montanide + Melan-A analog peptide + NY-ESO-1 analog 
peptide + MAGE-A10 peptide 
c) Montanide + CpG-7909/PF 3512676+Melan-A analog 
peptide + NY-ESO-1 analog peptide + MAGE-A10 peptide 
d) Montanide + CpG-7909/PF-3512676 + Melan-A native 
and analog peptides + NY-ESO-1 long peptide + MAGE-A10 
peptide 
e) Montanide + CpG-7909/PF-3512676 + Melan-A native 
and analog peptides + NY-ESO-1 long peptide + MAGE-A10 
peptide + low dose IL-2 
NCT00112242 
MART-1, 
b
tyr, 
gp100, MAGE-A3 
Duke 
University 
I Proteasome siRNA and tumor antigen RNA-transfected 
dendritic cells 
NCT00672542 
NY-ESO-
1/gp100/MART-1 
H. Lee Moffitt 
Cancer Center 
and Research 
Institute 
I Poly IC:LC, emulsified with Montanide ISA 51 with 
escalating doses of CP 870893 
NCT01008527 
MART-1 
/gp100/NY-ESO-1 
H. Lee Moffitt 
Cancer Center 
and Research 
Institute 
I MART-1:26-35 peptide vaccine, NY-ESO-1 peptide vaccine, 
anti-PD-1 human monoclonal antibody MDX-1106, 
gp100:209-217 peptide vaccine, gp100:280-288 peptide 
vaccine, Montanide ISA 51 VG 
NCT01176461 
MAGE-A3, Melan-
A, survivin 
Dermatologisc
he Klinik MIT 
Poliklinik-
Universitaetskli
nikum 
Erlangen 
I, II KLH, therapeutic autologous dendritic cells NCT00074230 
MAGE-A3, 
NA17.A2 
Cliniques 
universitaires 
Saint-Luc-
Université 
Catholique de 
Louvain 
I, II Vaccine MAGE-3.A1 peptide, or the NA17.A2 peptide + IL-2, 
IFN-α and GM-CSF, imiquimod. 
NCT01191034 
MAGE-A1 /MAGE-
A3,  
tyr/MART-
1/gp100 
Maria 
Sklodowska-
Curie 
Memorial 
Cancer Center, 
Institute of 
Oncology 
I, II a) HLA-A1-binding MAGE-A1/MAGE-A3 multipeptide-pulsed 
autologous dendritic cell vaccine 
b) HLA-A2-binding tyr/MART-1/gp100 multipeptide-pulsed 
autologous dendritic cell vaccine 
c) autologous melanoma lysate-pulsed autologous dendritic 
cell vaccine 
d) autologous melanoma lysate/tracer antigen KLH-pulsed 
autologous dendritic cell vaccine 
e) dendritic cell-idiotype-KLH 
NCT01082198 
MART-
1/gp100/tyr/NY-
ESO-1 
H. Lee Moffitt 
Cancer Center 
and Research 
Institute 
I, II Dendritic cell vaccine therapy, therapeutic autologous 
lymphocytes, fludarabine phosphate 
NCT00313508 
MAGE-A3 
(GSK1203486A) 
Glaxo Smith 
Kline 
II  NCT00706238 
gp100, MAGE-A3 M.D. Anderson 
Cancer Center 
II R848 gel NCT00960752 
MAGE-A3 
(GSK2132231A) 
Glaxo Smith 
Kline 
III Placebo NCT00796445 
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Regulation of CTA expression 
Based on the therapeutic limitations posed by their heterogeneous expression, 
significant efforts have been made to clarify the molecular mechanism(s) regulating CTA 
expression in neoplastic cells and the factors that influence their distribution in tumor 
tissues. The extent of methylation of selected CpG dinucleotides in CTA promoters appeared 
to be the main restricting factor for their expression. In fact, studies performed at the 
promoter level in neoplastic cells and tissues from melanoma, sarcoma, lung carcinoma, and 
gastric carcinoma patients (97) (98) (99) (100) revealed a direct correlation between the 
expression of different members of the MAGE family and the presence of hypomethylated 
CpG dinucleotides in their promoters. This correlation has been recently confirmed at the 
single cell level, demonstrating that the intratumoral heterogeneity of MAGE-A3 expression 
derives from the methylation status of specific CpG dinucleotides within the MAGE-A3 
promoter (101). Two major experimental evidences further support the key role of the 
methylation status of CTA promoters in determining their pattern of expression in neoplastic 
tissues: 1) the availability of transcription factors required for CTA expression in CTA-
negative neoplastic as well as in normal cells (97), and 2) the demonstration that in vitro 
methylation of CTA promoters is sufficient per se to block their transcriptional activity in 
cancer cells constitutively expressing high levels of CTA (98) 
 
HLA antigens 
Despite the adequate expression of therapeutic TAA on neoplastic cells, their 
efficient recognition and targeting by TAA-specific cytotoxic T lymphocytes (CTL) relies on 
the presence and levels of HLA class I antigen expression on the cell surface. Different 
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abnormalities in the expression of HLA class I antigens have been described, including total 
HLA class I antigen loss, total HLA class I antigen downregulation, HLA class I locus-specific 
loss or downregulation (102), and selective loss or downregulation of distinct HLA class I 
allospecificities (103). 
Regulatory and structural defects in genes involved in the biosynthesis of the 
peptide/β2-microglobulin/HLA class I heavy-chain complex appear to be the most frequent 
causes for the impaired expression of HLA class I antigens in cancer cells (103). However, 
recent evidence shows that epigenetic phenomena contribute to the generation of an 
altered pattern of HLA class I antigen expression in cancer cells. In fact, hypermethylation of 
CpG islands located in HLA-A, -B, and -C promoters correlated with downregulated mRNA 
and protein expression of HLA class I antigens in human esophageal squamous cell 
carcinomas, representing the major mechanism of transcriptional inactivation of HLA class I 
genes in this neoplasm (104). DNA hypermethylation also was found to be responsible for 
the downregulated expression of HLA class I antigens in metastatic melanoma (105), while 
its role in generating total HLA class I antigen loss phenotypes in malignant melanocytic 
lesions is debated (106). 
 
Immunomodulatory activity of epigenetic drugs 
Epigenetically silenced genes can be reactivated using specific inhibitors of the 
enzymes that establish/maintain epigenetic patterns. Among these, DNMT1 exerts a major 
role in maintaining DNA methylation patterns throughout cell replication (107), and the 
inhibition of DNMT1 activity leads to the synthesis of hypomethylated DNA (108). Among 
inhibitors of DNMT1, one of the most widely applied is 5-aza-2’-deoxycytidine (5AZA-CdR), 
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which is an aza-analogue of cytosine that is incorporated into DNA during the S-phase 
(108)of the cell cycle and covalently traps DNMT1, resulting in the synthesis of heritably 
demethylated DNA (108). 
 The exclusive role of DNA methylation in controlling their expression makes CTA ideal 
targets for 5-AZA-CdR–based epigenetic treatments aimed to induce or potentiate CTA-
restricted immune recognition of cancer cells. In fact, 5-AZACdR proved effective in both 
inducing (96) (97) (98) (109)CTA expression in neoplastic cells, in a lineage-independent 
fashion. More importantly, 5-AZA-CdR was able to establish a homogeneous level of CTA 
expression among single cell clones derived from a primary culture of metastatic melanoma 
cells, which constitutively expressed heterogeneous levels of MAGE-A3. These findings 
demonstrated the ability of 5-AZA-CdR to homogenize CTA expression within neoplastic 
lesions to be targeted by CTA-specific vaccination (101). The modifications of CTA expression 
induced by 5-AZA-CdR are considerably durable; in fact, drug-induced de novo expression of 
CTA was still detectable in cancer cells of different histotype cultured for 60 days after the 
end of 5-AZA-CdR treatment (105). Furthermore, when examining the effect at single cell 
level, CTA expression achieved through 5-AZA-CdR-induced promoter demethylation was 
found to become a constitutive feature of the cell, being inherited indefinitely throughout 
cell replications (110). This evidence is in accordance with the physiologic heritability of DNA 
methylation patterns in somatic cells (108). The imunomodulatory activity of DNA 
hypomethylating agents (DHA) is not restricted to the induction/upregulation of CTA but 
also influences several components involved in the presentation of TAA to the immune 
system, and in the recognition and lysis of TAA-positive neoplastic cells by CTL. In this 
respect, a key role in both presentation and sensitization to CTL lysis is played by HLA class I 
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antigens, which are frequently downregulated in cancer cells (103). 5-AZA-CdR was 
demonstrated to be an extremely efficient and reliable drug for upregulating HLA class I 
antigens and HLA-A1 and -A2 allospecificities in a large panel of metastatic melanoma cells 
(105). This drug-mediated upregulation of HLA class I antigens was persistent as compared 
to the short-lived activity of interferon- γ: after 5-AZA-CdR withdrawal, 32 days were 
required for HLA class I antigens expression to return to the baseline levels, whereas 12 days 
were sufficient for the reversal of interferon-γ effects (105). 
 The expression of accessory/costimulatory molecules involved in T-cell activation is 
also affected by DHA, indicating a broader immunomodulatory activity of these drugs. The 
upregulation of intercellular adhesion molecule-1 (ICAM-1) expression by 5-AZA-CdR was 
shared among neoplastic cells of different histologies, having been observed in melanoma 
(105), ovarian cancer (111), and renal cell carcinoma (RCC) cells (112); in contrast, the 
upregulation of leukocyte function-associated antigen-3 (LFA-3) was found to be restricted 
to melanoma cells (105).  
 Of prospective clinical relevance, the complex phenotypic modifications induced by 
exposure of neoplastic cells to epigenetic drug were shown: i) to significantly improve the 
recognition of cancer cells by antigen-specific cytotoxic T lymphocytes (CTL) (113); ii) to 
abrogate the intratumoral heterogeneity of CTA expression by neoplastic cells thus allowing 
for their homogeneous CTL recognition (101); iii) to increase the immunogenicity of 
transformed cells (113). 
Further supporting the immunomodulatory role of DHA, systemic administration of low-dose 
5-AZA-CdR induced a persistent de novo expression of the CTA MAGE-A1, SSX 1-5 and NY-
ESO-1 in peripheral blood and bone marrow mononuclear neoplastic cells of patients with 
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acute myeloid leukemia or myelodysplastic syndrome (114), and of MAGE-A3 and NY-ESO-1 
in tumor biopsies from patients with thoracic malignancies (115). These phenotypic changes 
associated with the development of a humoral response against NY-ESO-1 in selected 
individuals (115).  
 Altogether these evidences provide the scientific rationale for the use of DHA in the 
clinical setting to improve the efficacy of cancer immunotherapy. 
 
The melanoma methylome 
Melanoma is thought to arise through a series of genetic and epigenetic events. This 
most likely involves numerous irreversible changes occurring within the human genome, 
such as chromosomal deletions, amplifications, and gene mutations. Recently, however, 
epigenetic events have attracted more attention due to their central involvement in cancer 
development and potential of therapeutic intervention. Neoplastic transformation is 
accompanied by a complex deregulation of the cellular DNA methylation homeostasis, 
resulting in both gene-specific hypermethylation and genome-wide hypomethylation (116). 
Aberrant DNA hypermethylation is a frequent event in melanoma and acts as an 
alternate and/or complementary mechanism to gene mutation or deletion, resulting in the 
inactivation of specific gene expression and function of TSGs. To date, more than 50 genes 
have been identified to be aberrantly hypermethylated during different phases of melanoma 
progression and metastasis, as summarized in Table N. Although the exact function of most 
of these aberrantly silenced genes and their contribution to melanoma progression is still 
unknown, many studies suggest that they possess different gene functions, such as cell cycle 
control, apoptosis, cell signaling, tumor cell invasion and metastasis, angiogenesis, and 
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immune recognition (117). RAR-β2, which mediates growth arrest, differentiation and 
apoptotic signals triggered by retinoic acids (RA), together with RASSF1A, which promotes 
apoptosis and growth arrest, and MGMT, which is involved in DNA repair, are the most 
frequent and well characterized hypermethylated genes in melanoma, being methylated 
respectively in 70%, 55% (118-120) and 34% of melanoma lesions (118) (Table 2). Notably, a 
very high incidence of promoter methylation has been observed for genes involved in the 
metabolic activation of chemotherapeutic drugs (i.e., CYP1B1, methylated in 100% 
melanoma lesions (121), and DNAJC15, methylated in 50% melanoma lesions (121), which 
might contribute to the well-known resistance of melanoma cells to conventional 
chemotherapy. The list of genes hypermethylated in melanoma is continuously expanding, 
and it is including new genes that are hypermethylated in virtually all lesions examined (e.g., 
QPCT, methylated in 100% MELANOMA; LXN, methylated in 95% melanoma (121), though 
their function/role in melanoma progression has still to be addressed. Interestingly, some 
genes, such as RAR-β2, are found methylated with similar frequencies in primary and 
metastatic melanoma, suggesting their methylation as being an early event in melanoma, 
while others have higher frequencies in advanced disease (e.g., MGMT, RASSF1A, DAPK), 
suggesting the implication of their aberrant hypermethylation in disease progression (118). 
Besides TSG hypermethylation, genome-wide hypomethylation might contribute to 
tumorigenesis and cancer progression by promoting genomic instability, reactivating 
endogenous parasitic sequences and inducing the expression of oncogenes (122).  Recent 
studies demonstrated that extensive DNA hypomethylation in tumors occurs specifically at 
repetitive sequences, including short and long interspersed nuclear elements and LTR 
elements, segmental duplication and subtelomeric regions (123). These findings further 
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validate the role of DNA methylation in maintaining the stability of the human genome and 
the suppression of transposable elements in mammalian cells. In this contest,  Tellez et al 
measured the level of methylation of the long interspersed nucleotide element-1 (LINE-1) 
and Alu repetitive sequences to estimate the genome wide methylation status of melanoma 
cell lines. With this approach they were able to demonstrate that the extent of repetitive 
elements hypomethylation inversely correlated with the number of TSGs aberrantly 
inactivated by promoter hypermethylation (124). On the other hand, genome-wide 
demethylation has been associated with the de novo expression of tumor associated 
antigens belonging to the CTA family (97;98;101;109). Expression of CTA genes is repressed 
in normal human skin melanocytes, primarily due to heavily methylated promoter regions in 
a cell lineage-specific manner. Conversely, these same genes can exist in a demethylated 
state and are aberrantly re-expressed in subsets of melanoma cells. The biological 
significance of this gene re-expression continue to be poorly understood. A central question 
is whether the CTA expression contributes to tumorigenesis or is only a functionally 
irrelevant by-product of the process of cellular transformation due to global genome 
hypomethylation. Current evidence would suggest that reactivation of these genes may 
contribute to overall tumorigenesis. It is clear that the expression of these tumor antigens 
can result in their recognition and possible destruction by the host immune system. 
Importantly, recent data suggest that expression of MAGE genes in cancer cells contributes 
directly to the malignant phenotype and response to therapy (125). 
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Table 2: Genes with an altered DNA methylation status in human melanomA (adapted from (126))  
PATHWAY GENE METHYLATION 
STATUS IN 
MELANOMA
a
 
%  FREQUENCY SOURCE MODULATED 
BY 5-AZA-CdR 
       
APOPTOSIS 
 
DAPK
b
 methylated 19 16/86 tumors ND
c
 
HSPB8 methylated 69 11/16 tumors YES 
TMS1 methylated 50 5/10 tumors YES 
TRAILR1 methylated 80 8/10 cell lines YES 
XAF1 methylated NA NA cell lines YES 
RASSF1A 
methylated NA NA cell lines YES 
methylated 63 26/41 sera NA 
methylated 28 13/47 sera NA 
methylated 19 6/31 sera NA 
methylated 36 9/25 tumors YES 
methylated 55 24/44 tumors YES 
methylated 57 49/86 tumors YES 
CELL CYCLE 
CDKN1B methylated 9 4/45 tumors ND 
CDKN1C methylated 35 7/20 tumors YES 
CDKN2A 
methylated 76 31/41 sera NA 
methylated 10 3/30 tumors YES 
methylated 19 11/59 tumors ND 
TSPY methylated 100 
5/5 male 
patients 
tumors 
and cell 
lines 
YES 
CELL FATE 
DETERMINATION 
MIB2 methylated 19 6/31 tumors ND 
APC methylated 17 9/54 tumors YES 
WIF1 methylated NA NA cell lines YES 
DEGRADATION OF 
MISFOLDED 
PROTEINS 
DERL3 methylated 23 3/13 cell lines NO 
DIFFERENTIATION 
GDF15 methylated 75 15/20 tumors YES 
HOXB13 methylated 20 4/20 tumors YES 
DNA REPAIR MGMT 
methylated 63 26/41 sera NA 
methylated 19 6/31 sera NA 
methylated 31 26/84 tumors ND 
methylated 34 29/86 tumors YES 
DRUG 
METABOLISM 
CYP1B1  methylated 100 20/20 tumors YES 
DNAJC15 methylated 50 10/20 tumors YES 
EXTRACELLULAR 
MATRIX 
COL1A2 methylated 80 16/20 tumors YES 
MFAP2 methylated 30 6/20 tumors YES 
IMMUNE 
RECOGNITION 
BAGE demethylated 83 10/12 cell lines YES 
HLA class I methylated NA NA cell lines YES 
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PATHWAY GENE METHYLATION 
STATUS IN 
MELANOMA
a
 
%  FREQUENCY SOURCE MODULATED 
BY 5-AZA-CdR 
HMW-MAA methylated NA NA tumors 
and cell 
lines 
YES 
MAGE-A1 demethylated NA NA cell lines YES 
MAGE-A2, -
A3, -A4 
demethylated NA NA tumors YES 
INFLAMMATION PTGS2 methylated 20 4/20 tumors YES 
INVASION/ 
METASTASIS 
CCR7 no CpG island NA NA cell lines YES 
CDH8 methylated 10 2/20 tumors YES 
CXCR4 methylated NA NA cell lines YES 
DPPIV methylated 80 8/10 cell lines YES 
EPB41L3 methylated 5 1/20 tumors YES 
SERPINB5 
methylated 100 7/7 cell line ND 
methylated 13 5/40 tumors YES 
SYK methylated 30 6/20 tumors YES 
TFPI-2 methylated 29 5/17 tumors YES 
THBD methylated 60 12/20 tumors 
and cell 
lines 
YES 
PROLIFERATION WFDC1 methylated 20 4/20 tumors YES 
SIGNALING 
ERα 
methylated 24 26/109 Sera NA 
methylated 51 55/107 tumors ND 
PRDX2 methylated 8 3/36 tumors YES 
PTEN methylated 62 23/37 sera YES 
RARB 
methylated 13 4/31 sera NA 
methylated 20 5/25 tumors YES 
methylated 70 74/106 tumors YES 
SOCS1 methylated 76 31/41 sera NA 
SOCS2 methylated 44 18/41 sera NA 
SOCS3 methylated 60 3/5 tumors YES 
UNC5C methylated 23 3/13 cell lines NO 
VESCICLE 
TRANSPORT 
Rab33A methylated 100 16/16 
tumors 
and cell 
lines 
YES 
TBD BST2 methylated 50 10/20 tumors YES 
TBD FAM78A methylated 8 1/13 cell lines NO 
TBD HS3ST2 1\ 56 14/25 tumors ND 
TBD LRRC2 methylated 5 1/20 tumors YES 
TBD LXN methylated 95 19/20 tumors YES 
TBD PCSK1 methylated 60 12/20 tumors YES 
TBD PTPRG methylated 8 1/13 cell lines NO 
TBD QPCT methylated 100 20/20 tumors YES 
TBD SLC27A3 methylated 46 6/13 cell lines NO 
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a
, methylation status of the gene found in melanoma as compared to that found in normal tissue; 
b
, gene symbol: APAF-1, Apoptotic Protease Activating Factor 1; APC, adenomatous polyposis coli; BAGE, B 
melanoma antigen; BST2, bone marrow stromal cell antigen 2; CCR7, chemokine (C-C motif) receptor 7; CDH1, 
cadherin 1;CDH8, cadherin 8; CDH13, cadherin 13; CDKN1B, cyclindependent kinase inhibitor 1B; CDKN1C, 
cyclin-dependent kinase inhibitor 1C; CDKN2A, cyclin-dependent kinase inhibitor 2A; COL1A2, alpha 2 type I 
collagen; CXCR4, chemokine (C-X-C motif) receptor 4; CYP1B1, cytochrome P450, family 1, subfamily B, 
polypeptide 1; DAPK, death-associated protein kinase; DDIT4L, DNA-damage-inducible transcript 4-like; DERL3, 
Der1-like domain family, member 3; DNAJC15, DnaJ 
homolog, subfamily C, member 15; DPPIV, dipeptidyl peptidase IV; ENC1, ectodermal-neural cortex-1; EPB41L3, 
erythrocyte membrane protein band 4.1-like 3; ERα, Estrogen Receptor alpha; FAM78A, Family with sequence 
similarity 78, member A; GDF15, growth differentiation factor 15; HAND1, heart and neural crest derivatives 
expressed 1; HLA class I, human leukocyte class I antigen; HMW-MAA, high molecular weight melanoma 
associated antigen; HOXB13, homeobox B13; HS3ST2, heparan sulfate (glucosamine) 3-O-sulfotransferase 2; 
HSPB6, heat shock 
protein, alpha-crystallin-related, B6; HSPB8 heat shock 22 kDa protein 8; LRRC2, leucine rich repeat containing 
2; LOX, lysyl oxidase; LXN, latexin; MAGE, melanoma-associated antigen, MFAP2, microfibrillar-associated 
protein 2; MGMT, O-6-methylguanine-DNA methyltransferase; MIB2, mindbomb homolog 2; MT1G, 
metallothionein 1G; NKX2-3, NK2 transcription factor related, locus 3; NPM2, nucleophosmin/nucleoplasmin 2; 
OLIG2, oligodendrocyte lineage transcription factor 2; PAX2, paired box 2; PAX7, paired box 7; PCSK1, 
proprotein convertase subtilisin/kexin type 1; PGRβ, progesterone receptor β; PPP1R3C, protein phosphatase 
1, regulatory (inhibitor) subunit 3C; PRDX2, Peroxiredoxin; PTEN, Phosphatase and tensin homologue; PTGS2, 
prostaglandin-endoperoxide synthase 2; PTPRG, Protein tyrosine phosphatase, receptor type, G; QPCT, 
glutaminyl-peptide cyclotransferase; RARB, Retinoid Acid Receptor β2; RASSF1A, RAS associacion domain 
family 1; RIL, Reversion-induced LIM; RUNX3, runt-related transcription factor 3; SERPINB5, serpin peptidase 
inhibitor, clade B, member 5; SLC27A3, Solute carrier family 27; SOCS, suppressor of cytokine signaling; SYK, 
spleen tyrosine kinase; TFPI-2, Tissue factor pathway inhibitor-1; THBD, thrombomodulin; TIMP3, tissue 
inhibitor of metalloproteinase 3; TMS1, Target Of Methylation Silencing 1; TNFRSF10C, tumor necrosis factor 
receptor superfamily, member 10C; TNFRSF10D, tumor necrosis factor receptor superfamily, member 10D; 
TP53INP1, tumor protein p53 inducible nuclear protein 1; TPM1, tropomyosin 1 (alpha); TRAILR1, TNF-related 
apoptosis inducing ligand receptor 1; TSPY, testis specific protein, Y-linked; UNC5C, Unc-5 homologue C; 
WFDC1, WAP four-disulfide core domain 1; WIF1, Wnt inhibitory factor 1; XAF1, XIAP associated factor 1. 
c
, NA, 
not applicable; ND, not done; TBD, to be determined. 
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AIM OF THE STUDY 
Metastatic melanoma is a very aggressive disease, characterized by substantial 
unresponsiveness to conventional therapies and high mortality rates world-wide. Thus, new 
therapeutic options are urgently needed, especially for the advanced phase of the disease. 
Improved understanding of the biology of melanoma has led to the identification of 
molecular targets and to the recent development of novel therapies, which are showing very 
encouraging clinical results. Among the new therapeutic options with highly encouraging 
clinical results are targeted therapy with BRAF inhibitors and immunotherapy with 
therapeutic vaccines and immunomodulating monoclonal antibodies. 
More than 60% of human melanomas harbor BRAF mutations, especially the V600E 
(41), for which different selective BRAF inhibitors are being developed in clinical trials (68), 
showing impressive response rates in metastatic melanoma patients (ranging from 48% to 
81%) (70;71). On the other side, melanoma expresses a wide range of TAA. Among these, 
CTA represent ideal targets for active specific immunotherapy of patients with melanoma. 
Indeed, their frequent expression in melanoma cells, their limited expression in normal 
tissues and their in vivo immunogenicity (85), render CTA essentially tumor-specific 
therapeutic targets. 
The ultimate effectiveness of systemic targeted therapy based on BRAF inhibitors and 
of CTA-specific immunotherapy clearly relies on the consistency of activating BRAF 
mutations and of CTA-expression across metastatic lesions of a given patient.  In fact, wild-
type BRAF genotype or absence of therapeutic CTA make neoplastic cells unresponsive to 
treatment, and can be expected to drive clinical resistance to therapy and eventual 
progression of the disease. As far as immunotherapy, besides TAA expression, an additional 
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requirement for the effectiveness of treatments is the expression of adequate amounts of 
different “immune molecules” (e.g., HLA class I and class II antigens, accessory/costimulatory 
molecules) on melanoma cells. In this scenario, a major role in determing long-lasting 
therapeutic success of both targeted-therapies and immunotherapies is played by the 
maintenance of the target genotypic and phenotypic characteristics along with the clinical 
course of the disease, which ensures, in principle, the sustained responsiveness to 
treatment. 
In light of these notions, and to provide new molecular insights to possibly improve 
the clinical effectiveness of novel therapeutic options for melanoma patients, the present 
study aimed to characterize in-depth the presence of different promising therapeutic targets 
on melanoma cells along with the clinical course of the disease. The study took advantage 
from the availability of a large panel of short-term cell cultures obtained from metachronous 
lesions of metastatic melanoma patients. Tumor cell cultures were utilized in place of tumor 
tissues, to minimize the interference of contaminating normal cells, usually present in 
surgically removed neoplastic lesions, thus obtaining melanoma specific genotypic and 
phenotypic data. 
In particular the biomolecular characteristics investigated in melanoma cultures 
under study were: i) the BRAF mutational status; ii) the expression profiles of a large panel of 
TAA (CTA and differentiation antigens); iii) and of additional “immune molecules”(HLA class 
I, HLA class II, β-2 microglobulin, ICAM-1, LFA-1, LFA-3, HMW-MAA).  
Additionally, in light of the important role of altered DNA methylation in the biology 
of melanoma cells and in their immune recognition, further aspects evaluated in this study 
were: i) the maintenance of DNA methylation levels across the course of disease; ii) the 
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effect of DHA on gene expression profiles (GEP) and on the expression of immune molecules 
in melanoma cell cultures under study.  
The results obtained allow a more comprehensive characterization of the genotypic, 
epigenetic and phenotypic features of melanoma cells along with the course of the disease, 
providing the scientific background to design novel and potentially more effective 
therapeutic strategies for melanoma patients. 
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MATERIALS AND METHODS 
Patients, tissues and cells 
63 sequential metastatic melanoma lesions derived from 24 melanoma patients 
referred for surgery at the National Cancer Institute of Aviano (Italy) were processed after 
surgical removal and used to generate primary cultures of melanoma cells at the 6th-7th ex 
vivo passage. For the generation of primary cultures of melanoma cells, cells obtained by 
mechanical mincing and enzymatic digestion of tumor specimens were seeded in T25 tissue 
culture flasks in RPMI Medium 1640 (Biochrome KG, Berlin, Germany) complete 
supplemented with 20% heat inactivated FBS, 2 mM L-glutamine and 100 μg/mL penicillin 
(Sigma Chemical Co.), 100 μg/mL streptomycin (Bristol-Myers Squibb S.r.l). From 2 to 5 
metastatic lesions of each patient (mean: 2.6) derived from the 24 melanoma patients were 
snap-frozen in liquid nitrogen and stored at −80°C until RNA and DNA extraction was 
performed. 
 
BRAFV600E mutation quantification 
In the BRAFV600E lesions, we assessed the percentage of alleles carrying the mutation 
by pyrosequencing analysis, as previously reported by Edlundh-Rose et al (127). To perform 
this assay, which is based on ‘sequencing by synthesis’ principle, PCR amplifications were 
carried out with the following primers: 
 5’-biotin-TGAAGACCTCACAGTAAAAATAGG-3’ (forward)  
5’-TCCAGACAACTGTTCAAACTGAT-3’ (reverse).  
Samples were denaturated at 94°C for 5 min, amplified for 35 cycles consisting of 94°C for 30 
s, 58°C for 30 s, and 72°C for 45 s and elongated at 72°C for 7 min. The 5’-biotinylated PCR 
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products of the region including codon 1799 were immobilized onto streptavidin-coated 
paramagnetic beads (GE Healthcare), denaturated by 0.1 mol/l NaOH and released according 
to the manufacturer’s instructions using PyroMark Vacuum Prep Workstation (Biotage, 
Uppsala, Sweden). These reactions were performed in a 96-well plate using Pyro Gold 
Reagents (Biotage). The primed single-stranded DNA templates were subjected to real-time 
sequencing of the region including codon 600 by using the reverse primer 5’-
TGATTTTGGTCTAGCTACA-3’. A titration series with different dilutions of a sample containing 
the V600E mutation was set up to evaluate the linear correlation between the height of the 
peaks and the percentage of mutant alleles in the heterozygous lesions. These percentages 
were calculated by using PSQ96MA software (Biotage) for allelic quantification. 
 
Indirect immunofluorescence (IIF) 
Monoclonal antibodies, conventional antisera and reagents.  
The anti-HLA class I mAb TP25.99 and the anti-DR HLA class II mAb Cl413 were kindly 
provided by Dr. Soldano Ferrone (Department of Immunology, Roswell Park Cancer Institute, 
Buffalo, NY). The anti- intercellular adhesion molecule-1 (ICAM-1) mAb Cl203 and the anti-
LFA-3 mAb TS2/9 were purchased from Becton Dickinson. The anti-HMW-MAA mAb 763.74 
was purchased from Serotec. FITC-conjugated F(ab’)2 fragments of rabbit anti-mouse 
immunoglobulins (Ig) were purchased from DAKO. ChromePure mouse IgG were purchased 
from Jackson ImmunoResearch Laboratories, Inc. 
IIF analysis. 
 IIF was performed by incubating cells (1X105) with an excess of mAb at 4°C for 30 
min. After three washings with PBS supplemented with 0.5% BSA and 0.01% (wt/vol) NaN3 
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(PBSBSA-AZ), cells were incubated for an additional 30 min at 4°C with FITC-F(ab')2 
fragments of goat anti-mouse IgG (H + L) antibodies. After three washings with PBS-BSA-AZ, 
cells were resuspended in PBS-BSA-AZ and analyzed for surface fluorescence utilizing a FACS 
Calibur flow cytometer (Becton Dickinson Co., Mountain View, CA) and data were analyzed 
by the Cell Quest Software (Becton Dickinson). A sample was classified as positive when the 
mean value of fluorescence intensity was higher than 20. Mean value of fluorescence 
intensity obtained with isotype-matched mouse Ig was lower than 20 on all cell lines tested. 
 
Isolation of total RNA 
Total RNA was extracted by TRIzol Reagent (GIBCO BRL Co., USA). Cells were pellet by 
centrifugation at 1400 rpm for 5 minutes and then lysed by adding 1 ml TRIzol per 5 x 106 
cells. Following a 5 minute incubation at room temperature, 0.2 ml of chloroform per ml of 
TRIzol reagent was added to each tube and the resulting mixture shaken vigorously by hand. 
After centrifugation at 12000 rpm at 4°C for 15 minutes, the RNA-containing aqueous phase 
was transferred to a fresh tube and precipitated by adding 0.5 volumes isopropanol per ml 
TRIzol. The aqueous phase and isopropanol were mixed, kept at room temperature for 10 
minutes and then centrifuged at 12000 rpm at 4°C for 10 minutes. The supernatant was 
discarded and the RNA pellet washed in 1 volume of 75% ethanol per ml TRIzol to remove 
salt. The pellet was then air dried at room temperature and resuspended in DEPC H2O. RNA 
concentration and quality were determined using the NanoDrop ND-1000, a full spectrum 
(220-750 nm) spectrophotometer that measures 1 μl samples with high accuracy and 
reproducibility. 
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Digestion of RNA with DNASE I 
In competitive RNA-PCR studies, contaminating DNA can produce incorrect results 
because of its potential to act as a second competitor, so total RNA was digested with RNase 
free DNase I (Roche Diagnostics) to remove contaminating genomic DNA. 1 μl of DNase I 
reaction buffer (200 mM Tris-HCl pH 8, 500 mM KCl, 20 mM MgCl2) and 10 units of DNase I 
RNase-free (10U/μl) (Roche) were added per μg of RNA sample in 10 μl reaction volume. 
After incubation at 37°C for 30 minutes, DNase I was inactivated by heating at 65°C for 10 
minutes in presence of 25 mM EDTA (1 μl/μg of RNA sample). 
 
Retrotrascription  
2 μg of total RNA was used as a template for the reverse transcription (RT) in 20 μl reaction 
volume using Murine Leukemia Virus Reverse Transcriptase (M-MLV RT) (Invitrogen) and 
random hexamer primers (Promega). RNA, 1 μl random hexamer primers (0.5 μg/μl) 
(Promega), 4 μl 10 mM dNTP mix (10 mM each dATP, dGTP, dCTP and dTTP at neutral pH) 
(Invitrogen) and H2O added to 11 μl were incubated at 65°C for 5 minutes and quick chilled 
on ice with brief centrifugation. 4 μl 1st Strand buffer 5X (250 mM Tris-HCl pH 8.3, 375 mM 
KCl, 15 mM MgCl2) (Invitrogen), 2 μl 0.1 mM Ditiotreitol (DTT) (Invitrogen) and 2 μl RNase 
Inhibitor (40U/μl) (Invitrogen) were then mixed with contents of the tube and incubated at 
25°C for 10 minutes. Afterwards, 1 μl of M-MLV RT (200 U/μl) (Invitrogen) was added and 
the tube was transferred to a 37°C water bath for 50 minutes. The reaction was inactivated 
by heating at 70°C for 15 minutes and the volume was then adjusted to 100 μl with distilled 
water. 
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RT-PCR analysis  
Every PCR amplification was performed starting from 5 μl of cDNA in a total volume 
of 50 μl containing: 
PCR buffer 1x (100 mM Tris-HCl pH 8.3, 500 mM KCl) (Takara)     5 μl 
MgCl2 25 mM (Takara)          3 μl 
dNTPs 10 mM (Takara)          4 μl 
primers (sense+antisense) 100 pmoles/μl (Invitrogen)      1 μl 
Taq DNA polimerase (5U/μl) (Takara)              0.25 μl 
The oligonucleotide primer sequences and gene-specific PCR amplification programs used 
were reported in Table 3. The integrity of RNA and corresponding cDNA was confirmed 
through the amplification of  β-actin housekeeping  gene. Primers sequences, Temperature 
of annealing (TA), numbers of cycles and amplification length (bp) were reported in Table 3. 
Table 3: 
Antigen 
PCR 
Amplicon 
Length  
Primers TA 
Cycles 
n° 
ß-actin 615 bp 
F 5’-ggcatc gtg atg gac tcc g-3’ 
R 5’-gct gga agg tggaca gag a-3’ 
68°C 21 
MAGE-A1 421 bp 
F 5’-cgg ccg aag gaa cct gac cca g-3’  
R 5’-gct gga acc ctc act ggg ttg cc-3’ 
72°C 30 
MAGE-A2 230 bp 
F 5’-aag tag gac ccg agg cac tg-3’ 
R 5’-gaa gag gaa gaa gcg gtc tg-3’ 
67°C 30 
MAGE-A3 725 bp 
F 5’-tgg agg acc aga ggc ccc c-3’ 
R 5’-gga cga tta tca gga ggc ctg c-3’ 
72°C 30 
MAGE-A4 446 bp 
F 5’-gag cag aca ggc caa ccg-3’ 
R 5’-aag gac tct gcg tca ggc-3’ 
68°C 30 
MAGE-A6 725 bp 
F 5’-tgg agg acc aga ggc ccc c-3’ 
R 5’-cag gat gat tat cag gaa gcc tgt-3’  
72°C 30 
GAGE 1-6 239 bp 
F 5’-aga cgc tac gta gag cct-3’ 
R 5’-cca tca gga cca tct tca-3’ 
55°C 30 
NY-ESO-1 379 bp 
F 5’-cac aca gga tcc atg gat gct gca gat gcg g-3’ 
R 5’-cac aca aac ctt ggc tta gcg cct ctg ccc tg-3’ 
69°C 35 
SSX 1-5 663 bp 
F 5’-acg gat ccc gtg cca tga acg gag acg ac-3’ 
R 5’-ttg tcg aca gcc atg ccc atg ttg gtg a-3’ 
67°C 35 
MART-1 602 bp 
F 5’- ctgaccctacaagatgccaagag -3’ 
R 5’- atcatgcattgcaacatttattgatggag -3’ 
60°C  24 
Tyrosinase 284 bp 
F 5’- ttggcagattgtctgtagcc -3’ 
R 5’- aggcattgtgcatgctgctt -3’ 
60°C  36 
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The integrity of each RNA and random hexamer primers -synthesized cDNA sample 
was confirmed by the amplification of the β-actin housekeeping gene. 10 μl of each RT-PCR 
sample were run on a 2% agarose gel and visualized by ethidium bromide staining. 
 
Quantitative RT-PCR 
SYBR-green quantitative RT-PCR reactions were performed on 20 ng of 
retrotranscribed total RNA in a final volume of 20 μl SYBR-green Universal Master Mix 
(Applyed Biosystems) at 95°C for 10 min, followed by 45 cycles at 95°C for 15 s and at 60°C 
for 1 min, followed by dissociation performed at 95°C for 15 s, 60°C for 20 s and 95°C for 15 
s. SYBR-green primers sets were summarized in Table 4: 
 
Table 4: 
 
Antigen Primers  PCR Amplicon Length 
ß-actin 
F 5'-cga gcg cgg cta cag ctt-3' 
59 bp 
R 5'-cct taa tgt cac gca cga tt-3' 
MAGE-A1 
F 5'-gcc aag cac ctc ttg tat cct g-3' 
83 bp 
R 5'-gga gca gaa aac caa cca aat c-3' 
MAGE-A3 
F 5'-tgt cgt cgg aaa ttg gca gta t-3' 
74bp 
R 5'-caa aga cca gct gca agg aac t-3' 
NY-ESO-1 
F 5'-tgc ttg agt tct acc tcg cca-3' 
136 b 
R 5'-tat gtt gcc gga cac agt gaa-3' 
 
 
Measurement of gene expression was performed utilizing the ABI PRISM 7000 
Sequence Detection System (Applyed Biosystems, Milan, Italy) and the copy number of 
specific antigen and of the reference gene β-actin was established in each sample by 
extrapolation of the standard curve. The number of selected antigen cDNA molecules in each 
sample was then normalized to the number of cDNA molecules of β-actin. 
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LINE-1 bisulfite pyrosequencing analysis  
Genomic DNA was extracted from short-term cultures of melanoma cells by 
proteinase K treatment followed by standard phenol/chloroform extraction and ethanol 
precipitation (128). Bisulfite conversion was carried out on 500 ng genomic DNA using EZ 
DNA Methylation-Gold™ Kit (Zymo Research, Orange, CA, USA), according to the 
manufacturer’s protocol. Methylation analysis of the LINE-1 elements was performed as 
previously described (128), with minor modifications. LINE-1 elements were amplified using 
50 pmol each of forward primer 5’-TTTTTTGAGTTAGGTGTGGG- 
3’ and reverse biotinylated primer 5’-TCTCACTAAAAAATACCAAACAA-3’ in a 50 μL reaction 
volume containing 2.5 ng of bisulfite-treated DNA, 1× PCR buffer, 1.5 mM MgCl2 and 1.25 U 
of Platinum Taq DNA polymerase (Invitrogen, Milan, Italy). PCR thermal amplification profile 
consisted of an initial denaturation step of 5 min at 95°C, followed by 50 cycles of 30 s at 
95°C, 30 s at 58°C, and 1 min at 72°C. The PCR product was purified using Streptavidin 
Sepharose High Performance beads (Amersham Biosciences, Uppsala, Sweden) and 
denatured using 0.2 mol/L of NaOH solution. Next, 0.3 μmol/L of the sequencing primer (5’-
GGGTGGGAGTGAT-3’) was annealed to the purified singlestranded PCR product and the 
Pyrosequencing reaction was performed using the PSQ HS 96 Pyrosequencing System 
(Pyrosequencing, Inc., Westborough, MA). The level of methylation for each of the 3 
analyzed CpG sites (CpG1, CpG2, CpG3) was expressed as the percentage of methylated 
cytosines over the sum of methylated and unmethylated cytosines (Figure 1). Within- and 
between run variations for the determination of LINE-1 methylation through the 
pyrosequencing assay utilized have been previously described (128). 
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Treatment with 5-AZA-CdR 
Melanoma cell lines were seeded at a density of 2.5 X 105 cells/ml in a T75 tissue 
culture flask. Once cells became firmly adherent to plastic, medium was replaced with 8 ml 
of fresh medium, containing 1 μM 5-AZA-CdR, every 12h for 2 days (4 pulses). Flasks were 
wrapped in aluminum foil to avoid light exposure. At the end of treatment, medium was 
replaced with fresh culture medium without 5-AZA-CdR, cells were cultured for an additional 
48 h, and used for phenotypic and molecular assays. 
 
Gene expression profile 
The quantity and the quality of RNA, extracted as previous described, was assessed 
with NanoDropR ND-1000 UV-Vis Spectrophotometer (NanoDrop Technologies, Wilmington, 
DE, USA) and the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). In 
vitro transcription, labeling and purification of dye-labeled cRNA were performed using the 
Quick Amp Labeling Kit, one-color (Agilent Technologies, Santa Clara, CA, USA) following 
manufacturer’s guidelines. Gene expression profiling was performed by a One-Color strategy 
using Cy3-labeled aRNA from 6 metastases derived from 3 patients (Mel 195, Mel 201 and 
Mel 458) (Quick Amp Labeling, Agilent Technologies, Santa Clara, CA, USA). A mixture of 
1650 ng of Cy3-labeled reference cRNA, Blocking Agent and Fragmentation Agent was 
hybridized to Whole Human Genome (4x44K) oligo microarray platform (Agilent 
Technologies, Santa Clara, CA, USA). Hybridization was performed for 17 hours at 65°C in 2x 
GEx Hybridation Buffer HI-RPM (Agilent Technologies, Santa Clara, CA, USA), using Agilent’s 
Hybridization Oven at 10 rpm. Following washing, slides were analyzed by Agilent Microarray 
Scanner. Feature Extraction Software provided by Agilent (version 9.5.3) was used to 
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quantify the intensity of fluorescence images and to normalize results by subtracting local 
background fluorescence according to the manufacturer’s instruction. Differentially 
expressed genes between treated and untreated melanoma cell cultures  were selected with 
a cut-off set ≥3 for the Fold Change. 
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RESULTS 
Analysis of BRAF mutations in sequential melanoma metastases  
To evaluate whether the BRAF mutational status undergoes evolution with disease 
progression in melanoma, we assessed the activating BRAFV600E mutation in primary cell 
cultures generated from initial metastatic lesions surgically removed from 14 cutaneous 
melanoma patients and 18 subsequent metastases (Table 5).  
Pyrosequencing analysis revealed that genomic DNA of the sequential melanoma 
metastases,  removed from different body districts of individual patients at a median time 
interval of 302 days (range 26-1318), stabilized for the BRAFV600E mutated status. Indeed, the 
original heterozygous BRAFV600E status was consistently retained in 10 out of 14 patients 
investigated, while 2 out of 14 patients acquired a homozygous mutated status as compared 
to an initial heterozygous condition (Table 5). In contrast, no BRAFV600E mutation was 
acquired in 2 patients with an initial homozygous wild-type BRAF genotype (Table 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 
 
Table 5:  BRAFV600E mutation genotyping of sequential metastatic melanoma lesions  
Patient Metastasis 
# a 
Site of 
metastasis b 
Days c Percentage 
of mutant 
alleles d 
BRAF V600E e 
Mel 90 I  M 0 57.5 WT/MT 
 II M 71 58.9 WT/MT 
      Mel 91 I LN 0 55.5 WT/MT 
 II LN 238 58.8 WT/MT 
      Mel 120 I LN 0 55.7 WT/MT 
 III LN 672 64.2 WT/MT 
      Mel 140 I SC 0 61.4 WT/MT 
 II SC 411 70.4 WT/MT 
 III SC 728 92.9 MT/MT 
      Mel 146 I SC 0 66.3 WT/MT 
 II LN 254 67.7 WT/MT 
 III SC 554 66.7 WT/MT 
      Mel 195 I  LN 0 54.6 WT/MT 
 II SC 91 46.8 WT/MT 
     / Mel 201 I LN 0 57.4 WT/MT 
 II P 1318 84.8 MT/MT 
      Mel 255 I LN 0 58.8 WT/MT 
 II SC 292 52.1 WT/MT 
 III SC 299 55 WT/MT 
      Mel 261 I SC 0 42.4 WT/MT 
 II SC 305 35.9 WT/MT 
 III SC 721 33.6 WT/MT 
      Mel 435 I LN 0 7.2 WT/WT 
 II SC 139 7 WT/WT 
      Mel 458 I SC 0 0 WT/WT 
 II SC 26 0 WT/WT 
      Mel 532 I SC 0 58.2 WT/MT 
 II SC 364 46.8 WT/MT 
      Mel 554 I SC 0 45.3 WT/MT 
 II LN 118 44.9 WT/MT 
     / Mel 592 I LN 0 64.5 WT/MT 
 II LN 337 65 WT/MT 
      a Short-term cell cultures were established from initial (I) and subsequent sequential metastatic lesions removed 
from melanoma patients referred for surgery at the National Cancer Institute of Aviano (Italy). 
b
 M, muscle; LN, lymph node; SC, subcutaneous; P, pancreas. 
c
 Time frame of metastasis excision since the surgical removal of the first analyzed lesion.  
d
 Percentage of BRAF
V600E
 mutant alleles was determined by pyrosequencing assay.
 
e
 WT/WT, wild-type BRAF
 
homozygote (% BRAF
V600E
 < 25); WT/MT, BRAF
V600E
 heterozygote (% BRAF
V600E
 25 – 75); 
MT/MT, BRAF
V600E
 homozygote (% BRAF
V600E
 > 75). 
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Expression  of “immune molecules” in sequential melanoma metastases 
 To determine whether the expression of “immune molecules” is stable or undergoes 
alteration during disease progression, primary cell cultures from sequential metastatic 
lesions of 18 melanoma patients, were assessed for their antigenic phenotype by indirect 
immunofluorescence (IIF) analysis followed by flow cytometry.  
 Results reported in Table 6 demonstrated that the antigenic profiles of neoplastic cells 
of the same patient were mostly unstable through the course of the disease. Indeed, 16 out 
of 18 patients examined were characterized by alterations ≥50% of the mean fluorescence 
intensity values of 2 or more antigens investigated during disease progression. Noteworthy, 
data did not identify any univocal trend for variation of “immune molecules” in the course of 
the disease. In fact, though up-regulation of antigen expression levels along with tumor 
progression appeared to be more frequent (10 out of 18), down-regulation was also present 
(6 out of 18). Besides, mixed patterns showing concomitant up- and down-regulation of 
different antigens in the same patient were frequently observed (11 out of 18), suggesting 
that independent mechanisms of the antigens examined may affect the patients (Table 6). 
Noteworthy, changes in antigen expression did not appear to correlate neither with the time-
intervals to develop new metastatic lesions nor by anatomic site of metastasis. Among all 
investigated immune molecules, HLA class I was the less maintained in sequential metastases 
(2/15, 13.3%), while β2-microglobulin, ICAM-1 and HMW-MAA were the most maintained 
(7/18, 38.9%) (Table 6).Importantly, however, our data demonstrated that the majority of the 
antigens analyzed (HLA class I, β2-microglobulin, ICAM-1, LFA-1, LFA-3 and HMW-MAA) were 
frequently and highly express in the majority of patients, with the only exception of HLA class 
II, not expressed in all sequential lesions of 5 out of 19 patients (Table 6).  
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Table 6: Indirect immunofluorescence analysis of the antigenic profile of sequential metastatic 
melanoma cell cultures 
           
Trend
 d
 
Pts 
MTS 
#
a
 
days
b
 MTS site 
HLA 
class I 
b2m 
HLA 
class II 
ICAM-1 LFA-1 LFA-3 HMW-MAA M U D 
120 
I 0 LN 385
c
 497 316 49 77 5.7 534 
   III 672 LN 516 683 577 390 39.5 58.5 489 4/7 3/7 
 
140 
II 411 C/SC 43.7 133 19.5 130 73 30.9 132 
   
III 728 C/SC 128 163 171 120 47.8 13.9 125 4/7 2/7 2/7 
146 
I 0 C/SC 230 277 298 42 52 22 59 
   
III 554 C/SC 508 614 143 192 52.4 62 206 1/7 5/7 1/7 
195 
I 0 LN 137 149 60.2 12.3 30.4 94.4 205 
   
II 91 C/SC 242 277 149 106 46 18 173 1/7 5/7 1/7 
201 
I 0 LN 971 984 160 151 63 62 309 
   
II 1318 PA 270 531 52.7 129 74.7 514 447 4/7 1/7 2/7 
203 
I 0 C/SC 464 708 305 69.4 7.8 12.1 64.2 
   
III 468 C/SC 791 1140 21.8 131 60.6 31.5 148 
 
6/7 1/7 
IV 478 C/SC 520 813 3.6 122 69.3 21.9 145 6/7 
 
1/7 
255 
I 0 LN 423 526 97 395 108 55 382 
   
II 292 C/SC 156 216 11.5 40.2 38.4 34.3 250 2/7 
 
5/7 
256 
I 0 LN 385 661 8.5 176 182 62 984 
   
II 89 LN 824 1194 23.4 73.4 279 59.4 293 1/7 4/7 2/7 
261 
I 0 C/SC 99.2 108 31.1 294 44.3 34.8 120 
   
II 305 C/SC 478 803 134 466 32 11.9 214 
 
5/7 1/7 
III 721 C/SC 498 616 11.6 165 53.7 13.6 134 4/7 1/7 2/7 
318 
I 0 LN 95.8 740 143 54.5 119 84.2 148 
   
II 713 LN 86.8 820 8.5 87.8 114 80.2 192 5/7 1/7 1/7 
V 1484 LN 241 1082 29.3 88.5 164 28.8 197 4/7 2/7 1/7 
335 
I 0 C/SC 168 293 28.8 43.6 53.6 29.7 122 
   
II 91 C/SC 423 663 20.2 210 87.5 76.6 248 2/7 5/7 
 
435 
I 0 LN 429 664 5.1 194 193 63.1 15.2 
   
II 139 C/SC 267 428 4.5 135 128 41.8 33.6 7/7 
  
IV 180 M 1409 2134 20 153 227 67.4 7.85 1/7 5/7 1/7 
458 
I 0 C/SC 227 503 4.2 42.8 67.3 51.9 244 
   
II 26 C/SC 113 379 5.1 34 91.1 55.8 116 6/7 
 
1/7 
462 
IV 0 C/SC 211 398 6.1 238 58 33.3 269 
   
V 47 C/SC 173 328 11.3 82.5 51.1 15.1 137 5/7 
 
2/7 
VI 61 C/SC 131 203 40.5 170 94.5 13.5 292 2/7 4/7 1/7 
VII 120 C/SC 160 334 7.1 142 38.2 7.7 262 3/7 1/7 2/7 
532 
I 0 C/SC 93.8 235 7.5 66.9 89.9 8.6 40.9 
   II 364 C/SC 69.4 122 33.4 14.2 NT NT 54.1 2/5 1/5 2/5 
IV 607 C/SC 69.8 106.6 10.3 5.7 NT NT 153.9 2/5 1/5 2/5 
550 
I 0 LN 527 667 5.1 87 434 11 152 
   
II 102 C/SC NT 403 3.8 76.9 NT NT 35.6 2/4 
 
2/4 
554 
I 0 C/SC 528 655 146 59.3 138 9.5 345 
   
II 118 LN NT 540 15.4 54.2 NT NT 165 2/4 
 
2/4 
560 
I 0 C/SC 78.8 127 3.5 24.3 89.1 6.5 45.9 
   
II 108 L NT 137 3.3 28.6 NT NT 62.3 4/4 
  
        
 
NM mean fluorescence
 e
 13/15 11/18 14/18 11/18 8/13 11/13 11/18  
 M mean fluorescence
 e
 2/15 7/18 4/18 7/18 5/13 2/13 7/18 
        
 
a
 Cultures of melanoma cells established from initial (I) and subsequent sequential metastatic lesions, removed 
from cutaneous melanoma patients referred for surgery at the National Cancer Institute of Aviano (Italy), were 
sequentially incubated with antigen specific mAbs and with FITC-conjugated F(ab’)2 fragments of rabbit anti-
mouse Ig. Cells were then analyzed by flow cytometry. 
b
 Time frame of metastasis excision since the surgical removal of the first analyzed lesion.   
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c
 Mean values of fluorescence intensity. 
d 
Antigen-expression trend during the progression of the disease. M: maintained expression between sequential 
metastases in the number of antigens down-reported; U: up-regulated expression between sequential 
metastases in the number of antigens down-reported; D: downregulated expression between sequential 
metastases in the number of antigens down-reported. 
e
 Number of patients maintaining the antigen expression levels over time. M: variation < 50%; NM: variation ≥ 
50%. Abbreviations: LN = lymph node; SC = subcutaneous; C = cutaneous; P= pancreas; M= muscle; L= lung; 
MTS = metastasis; NT = non tested. 
 
 
CTA expression profiles in sequential melanoma metastases by RT-PCR analyses 
Total RNA of 63 primary cell cultures derived from sequential metastatic lesions 
surgically removed from 24 melanoma patients were analyzed for their constitutive 
expression of melanoma differentiation antigens (MART-1 and tyrosinase) and of a large 
panel of CTA (MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, NY-ESO-1, SSX 1-5, GAGE 
1-6) (Table N). From 2 to 5 metastases were analyzed from each patient (mean 2.6), and the 
median period between surgical removals dates of  metastases was 359.5 days (range: 26-
3131 days) (Table 7). 
As expected, RT-PCR analyses showed that the differentiation antigens were 
expressed in the majority of tumor samples, with percentages of positivity ranging from 
74.6% to 93.7% for MART-1 and tyrosinase, respectively. Almost all patients expressed these 
antigens in at least one lesion: MART-1 being expressed in 20 out of 24 patients, tyrosinase in 
23 out of 24 patients (Table 7). Concomitant absence of MART-1 and tyrosinase was observed 
in both metastatic lesions (I and II) of only one patient (Mel 554), and only in the first 
metastatic lesion of patient Mel 435 (Table 7). Results also demonstrated that the expression 
of MART-1 and tyrosinase was maintained in 19 out of 24 and in 21 out of 24 of patients, 
respectively. The other patients showed a common trend towards loss of antigen expression 
during the progression of the disease, with the only exception of patient Mel 435, who 
presented a negative first lesion for tyrosinase, while the second and the third were positive 
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(Table 7). RT-PCR analyses of CTA expression revealed that MAGE-A4 was the less prevalent 
(14 out of 24) in the melanoma patients under study, while MAGE-A1 and MAGE-A3 were the 
most expressed, being present in at least one lesion of all patients (24 out of 24) (Table 7). 
The comparison of sequential metastases from the same patient revealed that the expression 
of each CTA was maintained in over half of the patients (13 of 24) and it appeared not to be 
influenced by either temporal range between sequential metastases, nor anatomic site of 
metastasis (Table 7). Among all CTA examined, MAGE-A2 was the most stable among 
sequential metastases (maintained in 91.6% of patients), while MAGE-A3 and GAGE 1-6 were 
the less stable (maintained in 75% of patients) (Table 7). 
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Table 7: RT-PCR analysis of CTA and differentiation antigens expression in sequential melanoma 
metastases 
     CTA Differentiation antigens 
Pts MTS 
#a 
daysb MTS 
site 
β-actin MAGE-
A1 
MAGE-
A2 
MAGE-
A3 
MAGE-
A4 
MAGE-
A6 
NY-ESO-
1 
SSX  
1-5 
GAGE 
1-6 
  
 
MART-     
1 
tyrosina
se 
 
                
Mel 90 I 0 M + + + + + + + + +  + + 
 II 71 M + + + + + + + + +  + + 
                
Mel 91 I 0 LN + + + + + + + + +  + + 
 II 238 LN + + + + + + + + +  + + 
                
Mel 120 I 0 LN + - + + + - + + +  + + 
 III 672 LN + + + + + - + + +  + + 
 IV 762 SC + + + + + - + + +  - + 
                
Mel 140 I 0 SC + + + + - + + + +  + + 
 II 411 SC + + + + + + + + +  + + 
 III 728 C + + + + + + + + -  + + 
              
Mel 146 I 0 C/SC + + + + + + + + +  + + 
 II 254 LN + + + + + + + + +  + + 
 III 554 C/SC + - + + + + - + +  - + 
              
Mel 195 I 0 LN + + - - - - - - -  + + 
 II 91 C/SC + + + + - - - + +  + + 
              
Mel 200 II 0 M + + + + - + - + +  + + 
 IV 420 I + + + + - + - + +  + + 
              
Mel 201 I 0 LN + + + + - + - + +  + + 
 II 1318 P + + + + + + + + +  - + 
              
Mel 203 I 0 SC + + + + + + - + -  + + 
 II 76 SC + + + + + + + + +  + + 
 III 468 SC + + + + + + + + +  + + 
 IV 478 SC + + + + + + + + -  + + 
 V 504 SC + + + + + + + + +  + + 
              
Mel 255 I 0 LN + + + + - - - + +  + + 
 II 292 SC + + + + - - - + +  + + 
 III 299 SC + + + + - - - + +  + + 
              
Mel 256 I 0 LN + - - - - - - - -  + + 
 II 89 LN + + - + - - + + +  - + 
              
Mel 261 I 0 SC + + + + - + - + +  + + 
 II 305 C/SC + + + + - + - + +  + + 
 III 721 C/SC + + + + - + - + +  + - 
              
Mel 318 I 0 LN + + + + + + + + +  + + 
 II 713 LN + + + + + + + + +  + + 
 V 1484 LN + + + - - - + + +  + + 
                
Mel 335 I 0 C/SC + + + + - - + + +  + + 
 II 91 SC + + + + - - + + +  + + 
 III 168 SC + + + + - - + + +  + + 
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CTA  
Differentiation 
antigens 
Pts MTSa 
# 
daysb MTS 
site 
β-actin MAGE-
A1 
MAGE-
A2 
MAGE-
A3 
MAGE-
A4 
MAGE-
A6 
NY-ESO-
1 
SSX  
1-5 
GAGE 1-
6 
 MART
-1 
tyrosinase 
                
Mel 435 I 0 LN + + + - + + + + +  - - 
 II 139 C/SC + + + + + + + + +  - + 
 IV 180 M + + + + + + - + +  - + 
                
Mel 458 I 0 C/SC + + - - - - - - +  + + 
 II 26 C/SC + + - + - - - + +  + + 
                
Mel 462 IV 0 C/SC + - + - - + - - -  + + 
 V 47 C + - + + - - - - +  + + 
 VI 61 C/SC + + + + - - - - -  + + 
 VII 120 C/SC + - + - - + - - -  + + 
                
Mel 496 I 0 LN + + + + + + + + +  - + 
 III 3131 LN + + + + + + + + +  - + 
                
Mel 532 I 0 SC + + + + - + NT + +  + + 
 II 364 LN + - - + - + NT + +  - + 
 IV 607 C/SC + - - + - + - + -  - + 
                
Mel 542 I 0 LN + + + + + + + + +  + + 
 III 674 SC + + + + - - - + +  + + 
                
Mel 550 I 0 LN + + + + + + - - +  - + 
 II 102 SC + + + + + + - - +  - - 
                
Mel 554 I 0 SC + + + + + + + + +  - - 
 II 118 LN + + + + + + + + +  - - 
                
Mel 560 I 0 SC + + + + - - + + -  + + 
 II 108 POL + + + + - - + + -  + + 
                
Mel 592 I 0 LN + + + + + - + + +  + + 
 II 337 LN + + + + + - + + +  + + 
 III 2092 LN + + + + + + + + +  - + 
                
CTA expression 
frequency c 
   24/24 
(100%) 
22/24 
(91.6%) 
24/24 
(100%) 
14/24 
(58.3%) 
17/24 
(70.8%) 
16/23 
(69.5%) 
22/24 
(91.6%) 
23/24 
(95.8%) 
 20/24 
(83.3%) 
23/24 
(95.8%) 
                 
Maintained CTA 
frequencyd 
   19/24 
(79.1%) 
22/24 
(91.6%) 
18/24 
(75%) 
21/24 
(87.5%) 
21/24 
(87.5%) 
18/23 
(78.2%) 
21/24 
(87.5%) 
18/24 
(75%) 
 19/24 
(79.1%) 
21/24 
(87.5%) 
               
a
 Total RNA was extracted from short-term cell cultures established from initial (I) and subsequent sequential 
metastatic lesions removed from cutaneous melanoma patients referred for surgery at the National Cancer 
Institute of Aviano (Italy).  
b
 Time frame of metastasis excision since the surgical removal of the first analyzed lesion.   
c 
Number and percentage of patients, showing the CTA expression in at least a lesion.  
d
 Number and percentage of patients maintaining the CTA expression over time.  
Abbreviations: LN = lymph node; SC = subcutaneous; C = cutaneous; I = intestine; P= pancreas; M= muscle; L= 
lung; MTS = metastasis; NT = non tested. 
 
On the other hand, the expression profiles of investigated CTA resulted 
heterogeneous among the distinct sequential metastases in 11 out of 24 patients. A clear 
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pattern of gain or loss of 2 or more CTA along with disease progression has been observed in 
4 and 3 patients, respectively (Table 7 and 8). Furthermore, 4 patients were characterized by 
a high instability of CTA phenotype resulting in subsequent gain and loss or viceversa of the 
expression of different CTA over time (Table 7 and 8). 
Table 8: Melanoma patients with heterogeneous CTA expression profile. 
PZ 
MTSa 
# 
daysb β-actin MAGE-A1 MAGE-A2 MAGE-A3 MAGE-A4 MAGE-A6 NY-ESO-1 
SSX 
 1-5 
GAGE 
1-6 
N° CTA with 
modified 
expressionc 
Trendd 
              
Mel 140 I 0 + + + + - + + + + 
2 V  II 411 + + + + + + + + + 
 II 728 + + + + + + + + - 
              
Mel 146 I 0 + + + + + + + + + 
2 L  II 254 + + + + + + + + + 
 III 554 + - + + + + - + + 
              
Mel 195 I 0 + + - - - - - - - 
4 G 
 II 91 + + + + - - - + + 
              
Mel 201 I 0 + + + + - + - + + 
2 G 
 II 1318 + + + + + + + + + 
              
Mel 203 I 0 + + + + + + - + - 
2 V 
 II 76 + + + + + + + + + 
 III 468 + + + + + + + + + 
 IV 478 + + + + + + + + - 
 V 504 + + + + + + + + + 
              
Mel 256 I 0 + - - - - - - - - 
5 G 
 II 89 + + - + - - + + + 
              
Mel 318 I 0 + + + + + + + + + 
3 L  II 713 + + + + + + + + + 
 V 1484 + + + - - - + + + 
              
Mel 435 I 0 + + + - + + + + + 
2 V  II 139 + + + + + + + + + 
 IV 180 + + + + + + - + + 
              
Mel 458 I 0 + + - - - - - - + 
2 G 
 II 26 + + - + - - - + + 
              
Mel 462 IV 0 + - + - - + - - - 
4 V 
 V 47 + - + + - - - - + 
 VI 61 + + + + - - - - - 
 VII 120 + - + - - + - - - 
              
Mel 532 I 0 + + + + - + NT + + 
3 L  II 364 + - - + - + NT + + 
 IV 607 + - - + - + - + - 
            
  
Maintained 
CTA frequency
c
 
  
7/11 
(63,9/1%) 
9/11 
(81.8%) 
5/11 
(45,5%) 
8/11 
(72,7%) 
9/11 
(81,8%) 
5/11 
(45,5%) 
8/11 
(72,7%) 
5/11 
(45,5%) 
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a 
Total RNA was extracted from short-term cell cultures established from initial (I) and subsequent sequential 
metastatic lesions removed from cutaneous melanoma patients referred for surgery at the National Cancer 
Institute of Aviano (Italy).   
b 
Time frame of metastasis excision since the surgical removal of the first analyzed lesion.
  
c
 Number and percentage of patients maintaining the CTA expression over time.  
d 
CTA-expression trend during the progression of the disease.
 
Abbreviation: Pts = patient; MTS= metastasis; G = gain; L = loss; V= variable; NT = not tested. 
 
Quantitative evaluation of CTA expression levels in sequential metastases  
To confirm data obtained by qualitative RT-PCR, and to characterize the quantitative 
expression of CTA in sequential metastases, mRNA specific for MAGE-A1, MAGE-A3 and NY-
ESO-1 was measured by quantitative RT-PCR analysis on primary melanoma cell cultures from 
metachronous metastases of patients showing variable (Mel 146, Mel 195, Mel 203  and Mel 
458) or maintained (Mel 261) CTA expression profile over time by qualitative RT-PCR (Figure 
5). A complete agreement was observed between qualitative and quantitative RT-PCR results, 
positivity by qualitative RT-PCR being associated with levels of expression  ≥ 10-5 CTA mol /l 
β–actin mol. 
Furthermore, quantitative RT-PCR revealed that, beyond the qualitative changes in 
terms of presence/absence of CTA, melanoma patients with variable CTA expression profile 
among metachronous metastases showed also quantitative variations exceeding 2-folds 
(range: 2.02 -3874.78) among CTA-positive metastases. In contrast, no quantitative variation 
≥ 2-folds was observed in CTA expression levels among sequential metastases of Mel 261, 
which was characterized by stable CTA profile in qualitative RT-PCR analyses (Figure 5).  
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Figure 5: Quantitative RT-PCR analyses of CTA expression in sequential metastases from 5 melanoma 
patients. Retrotranscribed total RNA from primary cell cultures generated from metastatic lesions of each 
melanoma patient was subjected to SYBR green quantitative PCR reactions using MAGE-A1, MAGE-A3, NY-ESO-
1 and β-actin-specific primer sets. The expression of each gene was normalized to the expression of the 
housekeeping gene β-actin, and data were reported as gene cDNA molecules/β-actin cDNA molecules. 
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Genomic DNA methylation changes in sequential melanoma metastases 
 Alterations in DNA methylation, including genomic hypomethylation, are a common 
feature of human cancer and may provide a shared mechanism to generally impact on 
melanoma cell biology, including immune recognition of cancer cells. 
To define whether changes in the overall content of 5-methylcytosine occurr during 
melanoma progression, the extent of methylation of LINE-1 repetitive elements, used as 
surrogate of overall genomic DNA methylation, was analyzed in 45 primary cell cultures 
generated from sequential metastatic lesions surgically removed from 18 melanoma patients. 
DNA methylathion level was considered to be maintained when the difference 
between LINE-1 values of the sequential metastases was less than 5% (Figure 6). The mean 
difference in the percentage of LINE-1 methylation among autologous metachronous 
metastases was 4.69 (range 1.10-19.65), with both increase and decrease in methylation 
observed along with disease progression. Accordingly, most patients (10 out of 18) were 
shown to maintain the DNA methylation profile over time. No common trend towards 
hypomethylation/hypermethylation during disease progression was observed in the 
remaining patients. 
A decrease in methylation levels during the progression of the disease appeared to be 
associated with an acquisition of CTA expression, supporting the strong role of methylation in 
modulating CTA expression. Noteworthy, Mel 195 melanoma patient, who had a major 
decrease in LINE-1 levels during disease progression (Figure 6), showed a global gain of CTA, 
acquiring the de novo expression of 4 CTA (Table 7). These data were also supported by 
Spearman’s rank correlation analysis, which showed a significant (p≤0.05) inverse 
correlation between LINE-1 methylation levels and the number of expressed CTA (rho= -
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0.4881014) as well as the expression of MAGE-A3 (rho= -0.4650528), MAGE-A4 (rho= -
0.4097523) and  NY-ESO-1 (rho=-0.5138287) in the sequential metastases under study. 
 Interestingly, a marginally significative (p-value= 0.04) correlation was also observed 
between LINE-1 methylation and HLA class I antigen expression, though the correlation 
coefficent was low (rho: 0.35). 
 
 
 
 
Figure 6: LINE-1 methylation in sequential metastases.  
Representative histograms for the methylation levels of LINE-1, evaluated by bisulfite pyrosequencing analysis 
in short-term cultures of sequential melanoma metastases. All cells were analyzed at 6
th
-7
th
 in vitro passage. 
 
Activity of 5-AZA-CdR in sequential metastases 
It has been shown that treatment with DHA, like 5-AZA-CdR, can revert the 
costitutively heterogeneous inter- and intra-tumor expression of therapeutic CTA, suggesting 
a strategy to augment antitumor immunity in cancer patients. To investigate the possibility to 
revert the observed costitutive heterogeneity of CTA expression among different sequential 
melanoma metastases, primary cell cultures derived from 9 metastases of 4 patients, 
selected according to heterogeneity in CTA profile and LINE-1 methylation levels, were 
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treated in vitro with 5-AZA-CdR. RT-PCR analysis revealed that 5-AZA-CdR induced the 
expression of all investigated CTA (MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, NY-ESO-1, SSX 
1-5, GAGE 1-6) in all CTA-negative melanoma cell cultures, leading to a homogeneous CTA-
positive expression profile among autologous metachronous metastases of different patients 
(Table 9). 
 
Table 9: RT-PCR analysis of CTA expression in sequential melanoma metastases treated with 5-AZA-
CdR 
Pts MTS # treatment β-actin MAGE-A1 MAGE-A2 MAGE-A3 MAGE-A4 NY-ESO-1 SSX 1-5 GAGE 1-6 
Mel 146 
I 
ctrl + + + + + + + + 
5-AZA-CdR + + + + + + + + 
II 
ctrl + + + + + + + + 
5-AZA-CdR + + + + + + + + 
III 
ctrl + - + + + - + + 
5-AZA-CdR + + + + + + + + 
Mel 195 
I 
ctrl + - - - - - - - 
5-AZA-CdR + + + + + + + + 
II 
ctrl + + + + - - + + 
5-AZA-CdR + + + + + + + + 
Mel 201 
I 
ctrl + + + + - - + + 
5-AZA-CdR + + + + + + + + 
II 
ctrl + + + + + + + + 
5-AZA-CdR + + + + + + + + 
Mel 458 
I 
ctrl + + - - - - - + 
5-AZA-CdR + + + + + + + + 
II 
ctrl + + - + - - + + 
5-AZA-CdR + + + + + + + + 
a 
Total RNA was extracted from treated (5-AZA-CdR) or not (ctrl) short-term cell cultures, established from initial (I) 
and subsequent sequential metastatic lesions removed from 4 cutaneous melanoma patients referred for surgery 
at the National Cancer Institute of Aviano (Italy). RT-PCR analysis was performed using CTA-specific primer pairs. 
PCR products were then separated on a 2% agarose gel and visualized by ethidium bromide staining. 
 
 The anlysis was further extended in order to comprehensively characterize the effects 
of DHA treatment on melanoma cells from metachronous metastases. To this end, Agilent 
whole human genome microarrays were employed to define the remodelling of gene 
expression profiles (GEP), induced by 5-AZA-CdR on primary cell cultures, established from 
metachronous metastases of Mel 195, Mel 201 and Mel 458 patients. 
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Data analysis demostrated that, on average, the expression of 3890 genes (range 409-
4421) was modulated of at least 3 folds in metachronous melanoma cells under study, 
following 5-AZA-CdR treatment. To elucidate the biologic significance of the genes 
representing the expression signature of 5-AZA-CdR-treated vs untreated melanoma cells, 
the gene identifiers for the differentially expressed genes of all sequential metastases were 
linked to the “Onto-Express” web-based bioinformatic tool for global analysis of their 
function. As summarized in Table 10, among the highest scoring GO terms (considering 
p≤0.05 and number of associated genes ≥ 10) the most common biological processes 
modulated by 5-AZA-CdR treatment in melanoma cell cultures under analyses were: i) 
immune response (in 6 out of 6 metastases); ii) regulation of transcription (in 5 out of 6 
metastases) ; iii) cell adhesion (in 5 out of 6 metastases); iv) signal transduction (in 4 out of 6 
metastases); v) trascription (in 4 out of 6 metastases); vi) multicellular organismal 
development (in 4 of 6 metastases). Moreover,  a consistent up-regulation of several CTA 
genes (belonging to MAGE-A, MAGE-B, MAGE-C, SSX and GAGE families), which are well-
known as immune-related genes but are not included in the immunologic GO bioprocesses 
classes yet, was observed following 5-AZA-CdR treatment in all investigated cell cultures from 
autologous sequential melanoma metastases.  
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Table 10: Genes modulated by 5-AZA CdR in sequential metastases of 3 melanoma patients. 
Pts MTS # Biological process genes # p-value 
Mel 195  I signal transduction 84 0,002232 
  
regulation of transcription, DNA-dependent 43 6,51E-06 
  
immune response 39 4,14E-07 
  
transport 38 3,16E-04 
  
cell adhesion 35 0,003206 
  
transcription 32 5,85E-06 
  
cell-cell signaling 27 4,42E-06 
  
inflammatory response 25 4,80E-06 
     Mel 195 II immune response 20 4,66E-07
  
inflammatory response 14 1,99E-06 
  
cell differentiation 14 0,00266 
  
transport 14 0,009713 
  
G-protein coupled receptor protein signaling pathway 13 0,021904 
  
spermatogenesis 12 3,74E-05 
  
cell-cell signaling 10 0,002126 
  
apoptosis 10 0,030934 
     Mel 201  I signal transduction 148 1,50E-09
  
multicellular organismal development 91 7,43E-07 
  
regulation of transcription, DNA-dependent 64 5,44E-08 
  
cell adhesion 61 6,21E-07 
  
immune response 55 6,41E-09 
  
cell differentiation 51 6,00E-06 
  
G-protein coupled receptor protein signaling pathway 51 3,22E-04 
     
  
ion transport 51 5,45E-04
Mel 201 II signal transduction 131 1,69E-04 
  
multicellular organismal development 99 6,99E-08 
  
regulation of transcription, DNA-dependent 76 2,53E-06 
  
cell adhesion 62 2,08E-06 
  
immune response 55 4,82E-08 
  
proteolysis 54 2,64E-06 
  
transcription 53 9,46E-08 
  
ion transport 52 0,001174 
     Mel 458  I regulation of transcription, DNA-dependent 80 9,93E-04
  
multicellular organismal development 69 0,011538 
  
cell adhesion 60 4,26E-07 
  
transcription 48 3,11E-07 
  
ion transport 48 0,001371 
  
immune response 42 1,37E-04 
  
proteolysis 39 0,00557 
  
cell-cell signaling 30 1,41E-04 
     Mel 458 II signal transduction 247 3,07E-04
  
regulation of transcription, DNA-dependent 218 0,008199 
  
multicellular organismal development 197 -1,70E-11 
  
transcription 157 5,73E-05 
  
cell adhesion 132 1,30E-11 
  
cell differentiation 102 1,22E-08 
  
ion transport 94 0,00189 
  
immune response 75 0,001173 
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DISCUSSION  
 In this study we reported for the first time the concomitant characterization of 
metachronous melanoma lesions for the presence of novel attractive and promising 
therapeutic targets for the treatment of patients with melanoma, namely the targeted-
therapy target mutated BRAF and the immunotherapy target CTA. This was complemented 
by the characterization of metachronous melanoma cells for their expression of additional 
“immune molecules” required for their efficient immune recognition, their overall level of 
genomic DNA methylation and their sensitivity to GEP remodeling by DHA. 
The analysis of the activating BRAFV600E mutation in metachronous metastases of 
melanoma patients, revealed that, once melanoma reaches the metastatic stage, its 
BRAFV600E mutational status remains substantially unchanged in subsequent melanoma 
metastases, regardless of the time-intervals to develop new metastatic lesions and site(s) of 
further metastatization. These data are in line with a recent study by Lin et al, who reported 
a marked degree of intratumor heterogeneity for activating BRAF mutations in primary 
melanomas, on the contrary of a major stability and homogeneous presence of mutated 
BRAF in metastatic lesions of melanoma patients. The lack of further modifications in the 
BRAF mutational condition, once melanoma has metastasized, can possibly result from 
absent/limited intratumor heterogeneity for the mutation in the metastatic disease. This 
hypothesis has been supported by our recent study, which demonstrated that single cell 
clones generated from the short-term metastatic melanoma cultures of 2 patients retained 
the heterozygous BRAFV600E mutated and homozygous wild-type genotypes of the parental 
metastatic cells, respectively (129). The accurate definition of the “evolutionary biology” of 
activating BRAF mutation in melanoma progression bears important practical implications 
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since BRAF mutation in metastatic cutaneous melanoma is the molecular hallmark to select 
patients for treatment with the highly effective BRAF kinase inhibitors under active clinical 
development (70). Based on the data available, it appears that activating BRAF mutations are 
positively selected during melanoma progression until reaching the metastatic stage when 
the BRAF mutational status stabilizes. This finding, together with the likely limited intra-
tumor heterogeneity of BRAF mutations, suggests that the metastatic stage of BRAF mutated 
melanomas represents the most appropriate therapeutic setting for BRAF inhibitors. The 
highly stable BRAF status identified among metachronous melanoma metastases also bears 
important practical implications. In fact, any metastatic accessible tissue, either fresh or 
archival, regardless of the timing of metastasis and site of melanoma progression, being 
representative of the final BRAF mutational status of disease in a given individual, could be 
safely utilized to identify patients who are candidate to BRAF inhibitors. In clinical trials, 
treatment with selective BRAF inhibitors results in very high initial response rates which are, 
however, usually limited in time, with only a small proportion of patients who maintain a 
response for more than 12 months (68). The molecular mechanisms of melanoma resistance 
to BRAF inhibitors are being investigated, in order to develop therapeutic strategies for 
overcoming or preventing resistance. Initial data suggest that resistance to BRAF inhibitors is 
independent from the outgrowth of BRAF wild-type melanoma lesions (130). Being the BRAF 
mutational status stable over time in metastatic melanoma, it is reasonable to speculate that 
overcoming the BRAF inhibitors-induced intrinsic resistance of melanoma cells, could allow 
to continue or re-challenge patients with these highly promising therapeutic agents. 
On the other hand, preliminary evidence suggests that oncogenic BRAF may 
contribute to immune escape through down-regulation of melanocyte differentiation 
67 
 
antigens on tumor cells, and that blocking BRAF activity via inhibitors leads to increased 
expression of these antigens and to an improved recognition of melanoma cells by antigen-
specific CTL (131). Thus, combinations of BRAF inhibitors with immunotherapy may be 
another rational direction to pursue in the melanoma therapy, in order to take advantage 
both of the rapid and high response rates of BRAF-inhibitors and of the long-lasting disease 
control of immunotherapeutic approaches (131). 
Among different targets of immunotherapy, CTA represent ideal candidates for 
tumor-specific vaccination strategies, because of their restricted expression in neoplastic 
cells but not in normal cells, except in testis and placenta (two immune-privileged organs 
without MHC-I expression) and their ability to elicit a spontaneous humoral and cellular 
immune-response (132). Further emphasis on CTA as important targets for melanoma 
immunotherapy came from most recent data demonstrating that clinical response to 
immunotherapy with anti-CTLA4 monoclonal antibodies correlate with cellular and/or 
humoral immune responses against CTA (79). 
Despite the above reported advantages of CTA as therapeutic targets, an effective 
and durable clinical response to anti-CTA immunotherapies requires their homogeneous 
expression among all metastases of a given patient. In this context, very limited and 
discordant literature data are available about CTA-expression in synchronous and 
metachronous metastatic lesions of melanoma patients. In particular, Dalerba et al. 
demonstrated that CTA and melanoma differentiation antigens expression was 
homogeneous in the 82% of autologous metastatic lesions, collected from melanoma 
patients (133). Accordingly with this data, Sigalotti et al. have reported a maintained 
expression pattern of CTA and differentiation antigens among concomitant or sequential 
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metastases surgically removed from melanoma patients (98). Discordant results derived 
from other studies (134), which showed an unstable MAGE-A3 expression profile between 
sequential metastases (134) and reported that MAGE-A1 and MAGE-A4, but not NY-ESO-1, 
were acquired with advancing disease (135). 
Our studies aimed at shading light on these contrasting literature data, taking 
advantage of early in vitro passage autologous neoplastic cells from metachrounous 
melanoma lesions, which allowed precise evaluation of melanoma-specific CTA profile 
without the interference of the contaminating normal cells that are present at different 
extents in whole tumor tissues. Analyzing a wide panel of CTA, we showed that only 13 out 
of 24 melanoma patients analyzed maintained the profile of CTA expression among 
sequential autologous metastases. The remaining presented variable changes in CTA 
expression patterns along with disease progression, resulting in gain or loss of CTA without a 
common trend. Similar variations were observed also for the quantitative levels of CTA 
expressed by autologous metachronous lesions. The absence of a univocal trend of variation 
of CTA expression along with disease course remarks the current lack of knowledge of the 
role of CTA in melanoma progression, which may depend of different factors, including: i) 
the cellular contest of action; ii) the interaction of CTA-positive neoplastic cells with the host. 
Besides CTA, it appears that melanoma progression is accompanied by a general instability 
of the expression of molecules involved in the immune recognition of cancer cells, as 
evidenced by the variations in the levels of HLA class I, HLA class II, β2-microglobulin, ICAM-
1, LFA-1, LFA-3, and HMW-MAA observed among subsequent metastases. This overall 
instability of immune phenotype of melanoma cells along with disease progression clearly 
poses a major obstacle in long term systemic efficacy of melanoma immunotherapies. 
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In this context, the known role of DNA methylation in regulating the expression of different 
molecules involved in the immune recognition of cancer cells, strongly support the use of 
DHA to revert the heterogeneous expression of immune molecules among metachronous 
melanoma lesions, allowing their efficient targeting by the immune system. Support to this 
notion comes from our present findings demonstrating the ability of 5-AZA-CdR to generate 
a homogeneous CTA-positive phenotype among all primary cell cultures from metachronous 
melanoma lesions of investigated patients. Besides, a more comprehensive 
immunomodulatory activity of DHA on metachronous metastases could be recognized based 
on the finding that GEP profiling identified “immune response” as a shared biological process 
modulated by 5-AZA-CdR in autologous cell cultures. The clinical potential of DHA in 
improving immune targeting of melanoma cells is further sustained by pre-clinical in vivo 
studies demonstrating that systemic 5-AZA-CdR persistently induces and/or up-regulates the 
expression of CTA and HLA class I antigens on human melanoma xenografts (113). Along this 
line, initial studies on cancer patients showed that 5-AZA-CdR administration was able to 
induce long-lasting expression of CTA in both hematologic (114)and solid malignancies (115). 
Supporting the in vivo immunomodulatory activity of DHA, anti-CTA humoral immune 
responses were elicited in about 30% of patients in which de novo expression of CTA in the 
autologous neoplastic tissues was observed following treatment (115). Furthermore, a 
recent study showed that modifications of GEP induced by 5-AZA-CdR were preferentially 
restricted to tumour tissues and did not significantly affect normal tissues (Coral et al, 
unpublished). This represents a key learning in light of the clinical use of DHA as 
immunomodulatory agents. In fact, by preferentially targeting the sole tumour cells, DHA 
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should neither induce immune reaction(s) against normal tissues when utilized alone, nor 
increase that of immunotherapeutic agents in combination strategies (91) (136). 
Overall, our present results provide a comprehensive characterization of promising 
therapeutic targets currently evaluated for the therapy of melanoma along with tumor 
progression, and provide insights on potential strategies to improve therapeutic success. 
Among these, the broad immunomodulatory activity of DHA strongly support their use to 
improve effectiveness and applicability of CTA-based immunotherapies as well as of non-
specific immunotherapeutic strategies, such as immunomodulating antibodies (137), that 
are emerging as powerful therapeutic tools in solid tumours of different histotypes (81). 
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